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ABSTRACT
With the ever-increasing prevalence of atherosclerosis, procedures such as
angioplasty and stenting have become common practice, both of which are simple
techniques spouting relatively satisfying results for the past several decades. While
successful in opening of occluded vessels, these therapies can be met down the line with
thrombosis or even repeated occlusion of the vessel, known as restenosis. Similar to the
issues faced within oncology, treatment of this restenosis via widespread drug
administration throughout the body is not desirable. Cardiovascular and other medical
fields have begun looking into the use of magnetic nanoparticles as a drug delivery
vessel. Previously, our lab proposed the use of these particles to concentrate and carry
drug doses for local delivery as treatment of neointimal hyperplasia leading to restenosis.
This pairing would allow concentrated drug doses to be carried directly to the affected
vessel position, without adverse effects elsewhere in the vessel or even the entire body.
Prior work within our lab explored the viability of various drugs to be delivered,
determining the best candidate for experimentation to be heparin. This drug promised to
be an ideal candidate, as it has associations with both anti-thrombogenic properties as
well as anti-proliferative effects. Though currently in clinical use, heparin can have
adverse side effects, particular bleeding as a result of its effects on coagulation. However,
these strong properties, when administered locally via a magnetic vessel, should then be
advantageous.
Prior experiments worked to synthesize the full structure, coating the magnetic
nanoparticles with heparin through a process of polymeric additions and terminal group
exchanges. These were then characterized for size and surface charge to insure complete
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synthesis and heparin loading. Preliminary studies into the effects of these particles on
vascular smooth muscle cells (VSMCs) were conducted, showing promise for further
investigation into cellular effects and synthesis parameters.
This study seeks to expand upon these findings and continue gaining a broader
picture into the effect of heparin-coated nanoparticles on cell function. To provide a
system of controls, previous tests were repeated for VSMCs as well as 3T3 fibroblasts
(3T3s) and porcine endothelial cells (PECs). Using various assays for uptake,
proliferation, cytotoxicity, and phenotype, we can now propose the bigger picture for the
effects of these particles on a variety of cell lines found within the blood vessels. This
paper will present these new findings along with previous work conducted within our lab
to contribute to the big picture of the nature of these particles and their cellular
interactions.
Preliminary results of cell studies show promise for treatment at lower doses of
high heparin-loaded iron oxide nanoparticles, with optimal effects occurring around 1
µg/mL particles in media. Further cell and in vivo studies may be required to continue
optimization of this dosing, as most experimental conditions were conducted at much
higher concentrations. Some unexpected proliferation of endothelial cells occurred,
which may be beneficial to the vessel wall healing process. Further characterization of
particles showed successful synthesis and increased heparin loading from previous bulk
product. Future studies should optimize this heparin loading and finish full
characterization of particles, including effects on cell phenotype and particle magnetic
properties. The results from this study show promise for heparin-coated particles in far-
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future clinical use and also the need for further exploration into the calibration of
consistent particle synthesis.
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CHAPTER ONE
INTRODUCTION
1.1 Motivation
As the US population of baby-boomers continues to age, the healthcare community
begins to question whether we are prepared to meet their medical care needs. This
population segment now reaches an age group where the healthcare field, particularly
cardiovascular, is predicted to see a huge increase. Coupling this ‘booming’ elderly
population growth with general lack of preventative care has led to a poor outlook for
cardiovascular disease (CVD) prevalence and burden. Currently the leading cause of
death in the United States, CVD is projected to personally affect 40.5% of the population
by 2030, raising total direct and indirect costs to over $1 Trillion.1 Within CVD,
atherosclerotic cardiovascular disease (ACD) is the global leader in mortality.2 This has
led to continued huge increases in research and clinical trials for more effective treatment
for ACD. In ACD, arteries build up with plaque inside the lumen, limiting blood flow and
potentially causing problems such as heart attack, stroke, or death.3 This may occur in
important vessels throughout the body, reducing blood flow and supply of nutrients and
oxygen to vital organs. While primary treatment should focus on lifestyle changes and
preventative care, many patients eventually require intervention to remove or reduce the
blockage.
Within this exploding field, percutaneous coronary intervention (PCI) has become
a staple procedure, often utilizing stent and/or balloon angioplasty to clear these
obstructed arteries. While largely effective in clearing initial blockages, these procedures
are not without drawbacks, including restenosis, in-stent restenosis (ISR), or late in-stent
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restenosis (LISR), namely by neointimal hyperplasia. Current treatment options of
restenosis include systemic drug delivery and drug-eluting stents (DES), the latter of
which is becoming more highly used as preventative treatment. Further research at both
Clemson and abroad further look into new options such as drug-loaded balloons. As seen
within the realm of cancer chemotherapy, systemic drug delivery is highly invasive due
to the widespread negative side effects. DESs are far more effective in prevention, but
still show occurrence of restenosis, even long after the initial intervention. The
advantages and disadvantages of each of these will be discussed at greater length in a
later section.
This study hopes to continue discovery into the potential of heparin, a clinically
used and naturally occurring drug useful for both anticoagulation and antiproliferation,
two of the most damaging problems to face stents after application. Our goal is to further
characterize the usefulness of heparin when attached to a magnetic nanoparticle, such that
a non-systemic drug could be utilized to target stents showing signs of restenosis.

1.2 Research Aims
Aim 1: Confirm Past Results and Repeatability for Synthesis of Heparin-Coated
Magnetic Nanoparticles
Prior work conducted within our lab worked to synthesize and characterize
heparin-coated magnetic nanoparticles as a pilot study. The first aim of this study seeks
to reproduce these particles in similar quantity (bulk synthesis) and determine areas of
synthesis protocol that require further adjustment. For comparison, nanoparticles were
synthesized and measured for hydrodynamic diameter, zeta potential and heparin loading
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and compared to previously synthesized particle parameters. This new data will be
presented alongside previous data to demonstrate any batch dependencies. Previous
attempts have yielded high batch-dependent loading of heparin on the nanoparticles.
Special focus will be given to insure high heparin loading consistent with the initial
particle characterization.

Aim 2: Confirm Past Results and Repeatability for Effects of Heparin-Coated Magnetic
Nanoparticles on VSMCs
Additional prior work conducted within our lab worked to conduct preliminary
testing of the synthesized particles for their effectiveness and safety with the target cell
type, VSMCs. This preliminary study observed uptake of particles, toxicity of particles,
effects on proliferation and effects on phenotype by the distribution of alpha-smooth
muscle actin. These initial studies showed promising effects, even at low heparin loading
densities. This study repeats these tests with high heparin loading to validate and
optimize these findings and insure accurate reproduction of the coated particles. In
addition, these testing protocols were adjusted to insure accurate findings. Additional
imaging was tested to help verify results for the uptake of particles with short-term
exposure. Using these tests, further experiments can be designed to optimize heparin
loading and dose.
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Aim 3: Evaluate and Compare Effects of Heparin-Coated Magnetic Nanoparticles on
Other Relevant Cell Lines.
To add to the controls and evaluate effects of nanoparticles on other relevant cell
lines, similar tests were conducted to evaluate uptake, toxicity, proliferation effects, and
phenotype change of 3T3 fibroblasts and porcine endothelial cells. This is compared to
effects on VSMCs and used for aid in determining future experiments needed for full
particle characterization and dosing.

1.3 Significance
This study hopes to add to preliminary data collected within our lab to characterize
the properties and effects of heparin-coated magnetic nanoparticles. We now consider the
variety of cell lines present in a local vasculature system to gain a series of control
parameters for dosing. Thus, we can compare the benefits of nanoparticles loaded with
heparin to raw heparin in terms of both safety and efficacy on all effected/present cell
lines. Using the results from this study, further testing may be designed according to
optimal heparin dosing and nanoparticle concentration. The hope is for this therapy to
one-day offer a new, safe treatment option for neointimal hyperplasia.
1.4 References
1. P.A. Heidenreich, et al., “Forecasting the Future of Cardiovascular Disease in the
United States.” Circulation. 123:933-44. 2011.
2. S. Barquera, et al., “Global Overview of the Epidemiology of Atherosclerotic
Cardiovascular Disease.” Archives of Medical Research. 46(5):328-38. 2015.
3. “What is Atherosclerosis?” National Heart, Lung, and Blood Institute. 2015.
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CHAPTER TWO
PARTICLE COMPONENT PROPERTIES

2.1 Introduction
Though in use dating back to even the ancient Roman civilizations,1 nanoparticles
continue to be a hot topic for research in all academic fields. Their size gives them
fascinating properties, which can vary by small changes in the actual size of the particle.
Our study of nanoparticles and nanotechnology considers modern science and particles
on a scale of 1 to 100 nanometers,1 a range well within the realm of fascinating sizedependent properties. Though other broader definitions exist, within this scale the desired
properties are most pronounced.
Perhaps one of the most useful size-dependent properties of nanoparticles is the
relationship between particle surface area (SA) and volume (V). Using simple
proportions in terms of spherical radius, it is easy to see how quickly the ratio of SA:V
increases dramatically as radius decreases. This occurs as a result of SA changing with
the square of the radius and volume changing with cube of the radius. As a result of the
higher density of surface molecules, nanoparticles have highly reactive properties.2 The
results of this may additionally be seen in everyday life, including answering why the
same volume of sugar dissolves more quickly in hot tea when in a powder versus a cube
form. As we shrink below the size of 100 nanometers, many orders of magnitude smaller
than the sugar granules, these properties become severely more pronounced. For
example, gold, a typically inert element, has been found to be highly reactive at the
nanoscale and can even be used as a catalyst.3 Our very own bodies further use this
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functionality in many processes, including the digestive track,3 where high surface areas
allow much greater contact for absorbance of nutrients.
Today, nanotechnology is used in nearly every industry, much more commonly
than would be assumed. The National Nanotechnology Infrastructure Network says, “The
consumer world is exploding with ‘nanotechnology enhanced’ products.”4 In fact,
“nanostructured materials” may be seen across nearly all industries including food,
clothing, sports, electronics, and even medical products, just to name a few.4,5 These
‘newly discovered’ particle properties allow scientists and engineers to utilize unique
physical, chemical, mechanical, and optical properties of materials that are not present on
a bulk scale.1
In biology, nanoparticles hold several other benefits. Perhaps most obvious with
working on the nanoscale is the ability of cells to uptake particles, allowing interactions
between cells and nanoparticles. Whereas nanoparticles are on a scale of 1-100 nm, cells
are much larger and can range with dimensions between 10-100 µm for even the smaller
cells, with vascular smooth muscle cells near the top end of this range.6,7 With viruses,
proteins, and even genes on the same size-scale as nanoparticles,6 the potential for
biological applications is vast. In biomedicine, the ability of nanoparticles to maneuver
around the body and even into cells, along with the magnetic properties of various
nanoparticles, is currently in extensive use, specifically for cancer research.8 Specific
control of size and magnetic properties allows for heightened control of targeted drug
delivery rather than systemic drug delivery, the traditional approach to chemotherapy in
many types of cancer.9 Chemotherapy works roughly upon an approach to poison the
body just enough to effectively kill tumor cells without killing the patient. As a result of

6

this approach, some healthy cells are lost, resulting in many painful and dangerous side
effects. The potential benefits of moving beyond this drug delivery philosophy cannot be
overstated. In biological environments, other properties are also important, specifically
stability of the particles in aqueous solutions, body and room temperatures, near-neutral
pH, and physiologic salt concentrations.10
Equally important to our research is the coating on the nanoparticles. Heparin has
been chosen for review and experimentation, as it presents many desirable properties
related to the specific pathology, neointimal hyperplasia. Heparin is particularly useful
for research in this application as it operates as both an anticoagulant and antiproliferative
drug. Both naturally occurring and used clinically for treatment and prevention of
thrombosis,11 heparin presents as a strong candidate for nanoparticle coating for this
application. When paired together, the high SA/V ratios of nanoparticles allow for
pockets of highly concentrated drug,12 insuring larger dosing of heparin molecules into
cells at lower administered concentrations compared to raw heparin within solution.

2.2 Magnetic Properties of Nanoparticles
As nanoparticle properties are so size dependent, use in biomedicine requires
strict control of size to achieve desirable attributes. In synthesis, this is the one of the first
selected properties of the nanoparticles, and so proper selection and the impact on
properties is worthy of huge consideration. Among other previously discussed properties,
particle size on this scale can affect color, melting point, fluorescence, electrical
conductivity, chemical reactivity, and magnetic permeability; many as a result of the
greater important of quantum effects on behavior of particles.1 Small changes of size
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allows fine-tuning of these properties for various applications.1 For example, during
production of microtome slices, color changes can be seen with only thickness
differences of a few tens of nanometers. Within the magnetic nanoparticle realm, as
particles decrease in size, they begin to exhibit a special magnetic property known as
superparamagnetism (SPM), a form of magnetism where magnetization can randomly
flip direction over a relaxation time, as discussed below, under influence of temperature
and other environmental changes.6 To better address this significance, we shall first
discuss some standard magnetic concepts, and then how these relate to magnetic
nanoparticles.
Outside of the realm of SPM, materials are typically classified according to their
response to externally applied magnetic fields as diamagnetic, paramagnetic,
ferromagnetic, ferrimagnetic, or antiferromagnetic.12,13 In quantifying these properties for
a given material, we express the magnetization in terms of density of net magnetic dipole
moments. These moments determine the torque experienced within a magnetic field,
where torque is directly proportional to the product of magnetic moment of a sample and
the experienced external magnetic field.14 This torque tends to align with the applied
magnetic field, producing angular momentum. These magnetic types are well summed-up
by Prof. Steven Errede in his lecture notes on 4 types of magnetism, as will be discussed
below.13
We are perhaps most familiar with ferromagnetism, a very large, classic magnetic
force that results from quantum mechanics spins of electrons. The Pauli exclusion
principle explains the opposite spins of paired electrons, ordinarily canceling each other
out. However, in the case of ferromagnetic materials, unpaired electrons may have the
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same spin, generating what is known as a magnet moment. In these materials, spin
angular momentums of electrons create the magnetic dipole moment and thus a magnetic
dipole field. The overall magnetization of the material comes about as a result of the sum
of the magnetic moments, both in direction and magnitude. When these spins oppose and
lead to no overall magnetization, the material is known as antiferromagnetic. However,
ferromagnetic materials are energetically favorable for alignment and bulk magnetization.
Under external magnetic fields, these magnetic moments may align, allowing magnetic
attraction. This attraction occurs along a non-linear dependency, with attraction
strengthening greatly over shorter distances. These ferromagnetic materials, when
exposed to a strong enough external magnetic field can even reorient in parallel with that
field, creating what we know as a ‘permanent’ magnet. Once a permanent magnet,
ferromagnetic materials maintain their ordered magnetic states even when in the absence
of the external magnetic field. It should also be noted that these properties are
temperature dependent and are only present below the Curie temperature, a material
specific temperature above which magnetic materials lose their ferromagnetic properties.
Ferromagnetic materials include the commonly used magnetic nanoparticle metals of
iron, cobalt, nickel, and others.13
Less well known, diamagnetism looks at the production of small magnetic fields
by the orbital motion of electrons. Diamagnetism is present in all or nearly all materials,
but is the weakest as it tends to oppose applied magnetic fields. Under applied magnetic
fields, these current loops of unpaired electrons tend to align in opposition to the applied
field. Because of the electron field generation, most materials have diamagnetic
properties, though this may be overshadowed by other stronger magnetic contributions
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such as ferromagnetism.12,13 The diamagnetism properties of materials can further be
altered by the presence of circulating currents, forming stronger current loops of
electrons. One of the better-known materials to display diamagnetic properties is the
bismuth used in guns.13
Similar to diamagnetism, many materials exhibit some inherent sources of
paramagnetism from the electron spin at certain temperatures, according to the Curie
temperatures discussed earlier.12,13 This occurs by similar means as ferromagnetism, but
in much lessened magnitude. Paramagnetism operates proportionally in the direction of
the applied magnetic field with linear dependency.12 These materials are further
influenced by temperature, as thermal motion greatly influences the spin randomization
for this weaker magnetic property. Thus, similar to ferromagnetic materials,
paramagnetic materials display increasing magnetic properties at lower temperatures and
less magnetic properties at higher temperatures in accordance with Curie’s Law.13
However, despite this change, most paramagnetic properties are witnessed at higher
temperatures where other magnetic properties, particularly ferromagnetism, have been
lessened. Paramagnetic materials attract and repel like normal magnets under an external
magnetic field, but exhibit no magnetic properties once the external field has been
removed. Typical paramagnetic materials include aluminum, sodium, calcium, platinum,
and others. 13
As size decreases from bulk material to nanoparticles, additional magnetic states
are possible, namely the aforementioned SPM state. The small size of magnetic
nanoparticles allows them to be often simplified as single-domain particles, approximated
as one magnetic moment by the sum of atomic magnetic moments. This is in contrast to
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bulk material, where several domains are formed and may compete. Within this
simplification, magnetic nanoparticles typically show preference for a magnetization
alignment direction by spin rotation, as opposed to bulk materials, which react by net
movements of these domains in various directions. However, this direction can randomly
flip in the case of single domain nanoparticles with uniaxial anisotropy at the ends of a
relaxation time:6
𝜏 = 𝜏! 𝑒

(

∆!
)
!! !

(1)

Where:
•

τ0 : The length of time as a characteristic of the probed material.

•

ΔE : The energy barrier the magnetization has to overcome by thermal energy.

•

kB : The Boltzmann constant

•

T : The temperature

Thus, the relaxation time, or flipping of magnetic direction, is dependent on many
properties of the particle itself and environmental influences, such as temperature and
energy barrier. The SPM state of the nanoparticle system is observed when measured
over periods longer than the relaxation time such that the net moment is measured to be
zero. This relaxation state allows for the net moment to be zero whenever an external
magnetic field is not present. Whereas all materials can behave with paramagnetism,
paramagnetic behavior of ferromagnetic materials typically occurs, or is able to be
witnessed, above the Curie temperature. However, under external magnetic fields, these
SPM nanoparticles can behave as stronger paramagnets, even below the Curie
temperature.6 These properties, along with steric interactions with polymeric coatings
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allow magnetic nanoparticles to maintain in solution at room temperature without
agglomeration until exposed to an external magnetic field.
The full properties and ramifications of superparamagnetism are well reviewed by
Benz.6 Here, he reviews how these properties make magnetic nanoparticles particularly
useful in biomedicine. In short, he sums up that magnetic nanoparticles are especially
important for their size in comparison to targeted entities (as discussed previously), their
magnetic properties that allow magnetic field gradients to influence their movement, and
their ability to be resonantly excited allows heat transfer to surrounding tissues, the latter
of which will discussed at further length in a following section.

2.3 Magnetic Nanoparticle Property Selection
In addition to magnetic properties and previously discussed effects, nanoparticle
size plays a huge role within a biological system. For influence of cellular activities,
particles must be of size for correct uptake into cells, while still producing their desired
effect. For most biologic applications of drugs and nanoparticles, first pass by the liver,
spleen, and kidneys greatly reduces bioavailability.15 It has been found that particles less
than 10 nm are quickly filtered by the kidneys, while particles greater than 30 nm are
quickly filtered by the liver and spleen.16,17 This, along with level of synthesis difficulty,
leads many studies and applications to consider nanoparticles between 20 and 50 nm
diameters.14 With magnetic controls on nanoparticles, typically found to exhibit strong
SPM properties between 5-20 nm diameter,14 quick filtration by the liver tends to pose
much less of a threat.
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Metal nanoparticles can be made of a variety of materials, including gold and
silver nanoparticles, some of the most ancient and also most studied. As we progress
further into nanotechnology and its benefits, more and more materials become available
for commercial purchase as nanoparticles.18 While size is of such importance to
nanoparticle selection, as previously stated, nanoparticle material is of equal importance
for cell and biologic applications. Classically within the medical device market,
biocompatibility and cytotoxicity testing of bulk material remains as one of the primary
tested features.19 Specifically, in magnetically-targeted drug therapies, nanoparticles must
allow drug loading, be biocompatible once loaded, and exhibit strong magnetic
properties, as discussed in the previous section. Magnetic nanoparticles also come in a
variety of materials, including variations on alloys of a number of metals. Of these, some
of the most common include cobalt, nickel, iron oxides, or combinations of these metals
and other metals. For applications within the body, iron oxides are most commonly
employed as they exhibit less oxidation within the body than its magnetic competitors of
cobalt or nickel.16 This has led to widespread biomedical usage of iron oxides such as
magnetite (Fe3O4) and maghemite (γ-Fe2O3).16
With all magnetic nanoparticles, additional polymeric coating has shown a
relative increase in biocompatibility, perhaps due to prevention of agglomeration and
properties of the exposed surface to cells. In general, it has been accepted that for
biomedicine applications, magnetic nanoparticles and microspheres both must receive
coating in one of two configurations: magnetic core with a biocompatible polymer as
coating or porous biocompatible polymer in which magnetic nanoparticles can diffuse
through the pores.20 Due to synthesis methods, our bare metal nanoparticles were kept in
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either a solution of chloroform or tetrahydrofuran (THF), dependent on reaction step.
Because of this, bare metal particles would have been largely toxic to cells by solvent
alone. In other studies, bare metal nanoparticles have also been shown to be less
biocompatible than their coated counterparts.21 For example, one study suggested that
with poly(ethylene glycol) (PEG)-coated iron oxide nanoparticles, a polymer used in our
coating of magnetite nanoparticles, cells remained at relatively full viability at
concentrations as high as 1 mg/mL.22 This may be largely due to the exposure of cells
more directly to PEG rather than the interior nanoparticle. With biocompatible coatings,
much of the cytotoxicity would be as a result of the biocompatibility of the polymeric
coating and the breakdown/metabolism of this coating to expose nanoparticles.6 Similar
studies on uncoated nanoparticles have shown much higher losses in cell viability at
lower concentrations.23 With these particles, cell toxicity may be linked to cellular uptake
and production of a reactive oxygen species.14 Several studies have shown results over
prolonged exposure to iron oxide nanoparticles, displaying cytotoxic effects as a function
of cellular uptake and the resulting concentration.20,24,25,26 For comparative purposes in
our control particles, our nanoparticles all use a polymeric coating such that terminal
groups may be varied throughout full synthesis.
Several studies have further analyzed the effects of particle size during cellular
testing. Depending on the nanoparticle type and size variations, a number of effects may
be seen. These studies have shown statistically significant differences in resulting cell
toxicity, phenotype, and mechanical properties as a result of exposure to nanoparticles
varied by size.27,28 Additionally, these effects vary by both occurrence and severity of
effect by cell type.29,30,31,32 The effects of our particles are further influenced by both
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polymeric coatings, which increase the overall size significantly, and by the highly
concentrated drug additions.

2.4 Magnetic Nanoparticles in Biomedicine
Given this wide-range of properties, magnetic nanoparticles have found a wide
variety of applications within biomedicine. In particular, many researchers hope to use
the size control of magnetic nanoparticles for cancer therapies. Magnetic and other size
properties of nanoparticles offer up new chances at innovation into cancer cell and tumor
targeting. Some studies suggest that the ‘leaky’ vasculature system and lack of lymphatic
system of tumors may allow further targeting of cancer cells by size filtration.33 This may
allow fine-tuning of nanoparticle size to carry drugs directly to tumor sites, causing a
lessened systemic effect. In general, nanoparticles show promise for accomplishing other
previously difficult tasks, such as crossing the blood brain barrier or targeting antigen
expression of tumor cells.33
Once targeted to the site, nanoparticles offer a variety of therapy opportunities,
such as by drug-carrying vessels and for inducing localized hyperthermia. In this process
of hyperthermia, the goal is to heat and induce apoptosis in malignant tissue without
damaging benign tissue. This requires a specialized targeting system to reach the tumor
site, either by magnetic manipulation, size filtration by vasculature, direct injection, or
antibody marking.6,33 Once targeted to the desired tissue, magnetic properties of magnetic
nanoparticles, or any magnetic particles below 10 µm,6 may once again be utilized for
heat generation. Use of alternating/oscillating magnetic fields influences the spin natures
of both ferromagnetic and SPM particles, causing rapid rotation/flipping and heat
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generation. Using established kinetics of 30 min treatment at 42oC,6 localized
hyperthermia can be induced, triggering apoptosis mechanisms of local tumor cells with
minimal effects on benign tissue. A generalization of this process can be seen in Figure
2.1. Current advancements in this thermotherapy for cancer show promise for future
clinical use, with successful studies and innovated devices being released in both the
United States and Europe.20,34,35

Figure 2.1 Generalized concept for the use of magnetic nanoparticles for localized
hyperthermia by oscillating magnetic fields around the tumor site. Created by Andrade et
al. 201120 and reproduced in accordance to CC BY-NC-SA 3.0
Further nanoparticle targeting is used within biomedicine for magnetic separation.
This process uses a two-step procedure to both tag and manipulate the selected cell or
entity within solution.20 For separation of cells, the magnetic nanoparticle must also be
coupled with a biocompatible polymeric coating. This coating provides steric hindrance
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for increased stability and reduced toxicity of the particles for cellular uptake.36 These
polymeric coatings additionally provide an attachment site for antibodies and hormones,
allowing more specific targeting and binding systems.37 Using these antibodies,
nanoparticles may be specifically targeted for attachment to cell antigens, then mobilized
to separate cells from the solution. For this mobilization to occur, particles must be
manipulated by sufficiently strong magnetic forces, overcoming the hydrodynamic drag
from the surrounding solution.38 Figure 2.2 illustrates this general concept. In Figure 2.2
top), the capability of separating magnetic solution components from solvent in
demonstrated. Figure 2.2 bottom) shows an example of this technology in application,
where functionalized nanoparticles may be used for specific targeting and binding for
separation and removal.
Unfortunately, though Figure 2.2 top) shows a romanticized version of magnetic
separation, this process is often not instantaneous. Rather, speed of separation is also
largely dependent on particle size, where larger particles move through solution faster
than smaller particles, a process known as magnetophoretic mobility. While larger
particles (on the scale of microns) offer faster magnetophoretic mobility, they tend to
cause greater interference post-separation.39,40 Thus, though this process of separation
does work using just a permanent magnet adjacent to the container, other more efficient
methods may be employed, such as by magnetic field gradients in a quadrupolar
arrangement in a flow column.41 Clinically, this may one day be used to remove tumor
cells from blood circulation.42 Other future applications may use the size-dependence on
magnetophoretic mobility. Within lab, we can also use this property to separate
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agglomerated nanoparticle from solution, removing particulates that would otherwise
clog up filtration and purification methods.

Figure 2.2 top) Use of magnetic forces to concentrate or pull magnetic
nanoparticles out of solution.43 bottom) Magnetic separation example for selective
removal of another solute using functionalized magnetic nanoparticles.44
18

Also within clinical use, nanoparticles may be used for MRI Contrast Imaging.
Current MRI imaging uses a very powerful magnetic field to observe proton alignment.
Though the protons would typically be spinning with their axis oriented at random, under
strong enough magnetic fields (typically between 0.5 and 1.5 tesla),45 these axes will
align. Though relatively few protons would be aligned, the shear number of total protons,
abundant in water and fat, makes imaging possible.46,47 As these protons return to a
disoriented state, the relaxation signal is measured by loss of energy as heat and imaged
in the form of a radio wave.45,48,49 Detection of the intensity of this radio wave form can
be used from across the body to build up a cross sectional image. A series of pulses
measure the rates at which different tissues relax, providing contrast in the intensity
plot.45 Figure 2.3 Demonstrates this alignment of protons.

Figure 2.3 Left) Random alignment of hydrogen proton axes. Right) Under
influence of magnetic field, axes will align.45
Using magnetic nanoparticles as contrast agents, in place of the less magnetic
hydrogen protons found naturally in the body, this relaxation time may be shortened.20
19

Gadolinium is commonly used today, though magnetic nanoparticles have many
advantages that may lead to more extensive use in the future.50 These smaller particles
can still exhibit the useful magnetic properties for heightened contrast, but may be more
easily removed and filtered from the body via the kidneys, as discussed above. At the
same time, the small size does not compromise MRI resolution. To date, a number of
commercially

available

products

exist,

typically

employing

iron

oxide

nanoparticles.51,52,53

Figure 2.4 MRI images of rat brain glioma before and 20 minutes after injection of
gadolinium nanoparticles. The tumour and surrounding tissues are revealed by the effect
of the particles on the MRI signal.54
2.5 Magnetic Nanoparticles for Targeted Drug Delivery
As discussed in the previous section, magnetic nanoparticles show promise for
targeted drug delivery by the nature of their small size. Additionally, there is further hope
for localized delivery of drugs utilizing their magnetic properties. Many current drug
delivery methods rely on systemic delivery, or the non-specific distribution of
chemotherapeutics throughout the body. This may be administered via a variety of routes,
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including orally and intravenously,15 the most commonly known among many other
options. Unfortunately, drug administration in these methods inherently results in
unwanted effects and/or quick filtration, thus leading to higher required dosage.55 These
side effects from widespread distribution limit the effectiveness of drugs, which must
have reduced dosing to limit toxicity, but at the same time must have increased dosing to
maintain concentrations after the first liver pass.15 This paradox has led to extensive
research in ‘smart’ drug delivery technology, many of which seeks to utilize the desirable
properties of both nanoparticles and polymers. One day, this may lead to further work on
personalized medicine as well.
The NIH National Institute of Biomedical Imaging and Bioengineering summarizes
these advances into four categories: route of delivery, delivery vehicle, cargo, and
targeting strategies.55 Nanoparticle technology plays roles in many of these categories,
but is largely rooted in advancements for delivery vehicle and targeting. These carriers
are used to ensure delivery of medication to the targeted site, both by custom designed
biodegradable or magnetic nanoparticle systems. The carrier technology being developed
is vast and expands into nanotubes, nanomachines, nanofibers, nanomembranes, and
nano-sized silicon chips just to name a few.56
Some research, including our own, is being conducted into the potential of magnetic
nanoparticles for targeted drug delivery. Many of these proposed methods focus on
injection of the particle/drug combination near the site via a catheter, where it may be
immediately concentrated to the desired area for application.57 In these applications,
magnetic fields are focused over the target site, or in some cases implanted into the
body.57,58,59 Implantation within the body reduces the distance causing weakening of the
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magnetic field gradient. Our research would focus on this type of application, introducing
drug-coated magnetic nanoparticles proximal to the affected vascular area via a catheter
and treating the stent as an implantable ferromagnet. This concept may be seen in Figure
2.5 Theoretical models have predicted a wide range of required magnetic field gradients,
depending on application and vessel type. One animal trial suggested that forces as high
as 27 T/m may be required for some manipulations.60 Use of implantable magnets, stents,
or meshes reduces the distance to particles, thus reducing the overall magnetic force
required.

Figure 2.5 Targeted delivery of magnetic nanoparticles to a vascular wall. A) Depiction
of classical magnetic nanoparticle drug delivery using strong magnetic fields produced
and targeted outside of the body. B) Alternative suggested delivery of magnetic
nanoparticles using a catheter and targeted using a magnetic stent. Created by Chorny et
al. [1][2][6-8][1][1] and reproduced with permission.61
This coupling of particle and drug allows endless possible uses, where drugs and
their carriers can be designed specific to disease with more effective and accurate dosing.
This process shows potential for effectively eliminating the unintended adverse reactions
many systemically administered drugs and chemotherapies have on the rest of the body.
Once targeted to the site, the drug may be immediately effective while attached to the
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carrier particle or decoupled by degradation from enzymatic activity, physiologic
conditions (such as temperature and pH), or other established biodegradation
mechanisms.42,62,63,64
Within magnetic targeting, physiologic conditions pose a number of threats to drugmagnetic nanoparticle coupled systems. Within the body, many administration methods
will subject the drug to blood circulation, body temperature, pH changes, mechanical
forces, and immune responses.15 Thus, a number of considerations must be taken,
including calculated required magnetic force, degradation mechanism and kinetics,
toxicity of degraded parts, and drug administration/distribution methods. With proper
considerations, targeted drug therapies, whether by magnetic targeting or otherwise,
demonstrate potential use in any application where widespread distribution is not desired.

2.6

Natural Occurrence of Heparin
One briefly mentioned benefit of heparin is its relative biocompatibility, due
largely to natural occurrence in the body, and thus its ability to coat and improve the
biocompatibility of other materials.65 It should be noted that heparin can be easily
confused with heparan sulfate, which shares the same polysaccharide backbone structure
characterized by a large number of negatively charged functionalities and is found in
virtually all human cell types.66,67 Heparin on the other hand is a naturally produced
polymer classified as a mucopolysaccharide or a glycosaminoglycan (GAG) with a mean
molecular weight of 15kDa.68,69 Heparin consists of repeated disaccharide units
consisting of 1,4-linked L-iduronic acid (which are O-sulfated at position 2) and Dglucosamine (which are N-sulfated and O-sulfated at position 6). The heavily sulfated
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chains give heparin its high negative charge density. Heparin works largely due to its
strong electronegative charge, the result of having the highest negative charge density of
any known biological molecule.67 This also results in its propensity to bind to positively
charged proteins and surfaces.68,70 The chemical structure of heparin may be seen below
in Figure 2.6

Figure 2.6 Heparin molecular structure.67

Heparin is typically produced in the body by mast cells and blood basophils in
connective tissues,67,71 and is especially present in the liver, lungs, and mucosa where it is
used for both anticoagulant and lipotrophic properties.69,71 Within the body it acts as an
antithrombin factor to prevent intravascular clotting.71 Here, it inactivates both thrombin
and activated factor X (factor Xa), among other proteases, by activating antithrombin III
(AT3) through a conformation change, exposing reactive sites.67,68 For this mechanism,
heparin may increase the rate of inactivation by up to 1000-fold, efficiently inactivating
key molecules within the coagulation cascade for formation and activation of platelets
and factors V and VIII.67,68 Figure 2.7 demonstrates the addition of heparin (bound to the
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now activated antithrombin III) into the coagulation cascade and its inhibition of factors
upstream of the clot formation. Effectiveness as a more natural anticoagulant has led to
extensive clinical use as a drug, as discussed in the next section.

Figure 2.7 Intrinsic and Extrinsic Coagulation Cascade. This diagram demonstrates
the action of various drugs, including heparin for coagulation inhibition.72
2.7 Heparin in Biomedicine
As discussed in the previous section, heparin’s naturally occurring effects within the
body have led to its use as a clinical aid. Though it occurs naturally within the body,
heparin is typically sourced from pig intestines for clinical use.67 By shear volume of
clinically used heparin, sales revenues in the United States are in excess of $5 billion a
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year.67 Used clinically as an anticoagulant for decades, experimental evidence is
suggesting many other potential uses including as an inhibitor for inflammation, VSMC
proliferation, and metastatic spread of tumor cells.73 It should also be noted that heparin
does not work to break down formed clots, but rather inhibits clot formation and allows
the body’s natural clot lysis mechanisms to function more efficiently.67 As such, heparin
may be used as an anticoagulant for a number of conditions and procedures including
acute coronary syndrome, atrial fibrillation, deep-vein thrombosis and pulmonary
embolism, cardiopulomonary bypass for heart surgery, ECMO circuit for extracorporeal
life support, hemofiltration, and indwelling central of peripheral venous catheters.67
With a high negative charge and large size (in high molecular weight chains), heparin
is not absorbed by the gut, and is largely ineffective for use by oral administration.67,74
Instead, clinically it may be injected intravenously or subcutaneously, though
intramuscular injections are typically avoided to reduce risk of hematoma formation. [34]
Once administered into the body, heparin has a half-life of one to two hours, often
requiring continuous infusion.67,75 Other advances in low-molecular-weight heparins
(LMWH) have lengthened this half-life, reducing need for continuous dosing.67,74 In most
cases, heparin may be used alongside other anticoagulants for quick action, followed by
easier, oral therapies.67 For nanoparticle modification, we used a LMWH with a
molecular weight of 3000 g/mol.
This use of LMWHs has become more widespread in the last few decades, as it
overcomes many of the previous limitations of their heavier counterparts.
Depolymerization of unfractionated heparin into LMWHs reduces many of these
limitations, as these heparins all see reduced binding to proteins and cells.76 In essence,
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the smaller size results in fewer negatively charged binding sites. Though it works under
the same mechanisms as unfractionated heparin, the kinetics and abilities are affected.
Like it’s predecessor, LMWHs have been shown to be very safe and effective for a wide
variety of applications. For our purposes, the improved feature of predictable dose
response,74,76 along with other benefits, makes LMWHs a perfect candidate for drug
coating on our nanoparticles.

2.8 Conclusions
This study seeks to combine this background knowledge into a clinically relevant,
coated nanoparticle for the treatment of neointimal hyperplasia. With the control of sizedependent properties, magnetic nanoparticles offer huge potential for localized treatment
of diseases such as neointimal hyperplasia with far greater outcomes than systemic drug
therapies. When paired with heparin, cells can uptake and interact with a naturally
occurring, biocompatible drug on a larger scale, thanks to nanoparticle surface areas.
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CHAPTER THREE
VASCULAR CELL LINES

3.1 Introduction
Every successful surgical procedure, while fulfilling its primary goal, generates
new stresses on both a macroscopic and microscopic level. Within PCI, angioplasty
involving both stents and balloons results in additional stresses to the vascular interior
and alters the local environment. Understandably, this can cause cells to behave and react
in strange ways. Most notably damaging in treatment of vessel occlusion is by restenosis,
or the narrowing of a vessel following PCI procedures. This occurs by early thrombosis
formation, long stage myointimal proliferation, or a combination of the two.1 In essence,
angioplasty procedures produce stress upon vessel walls, which can be further
exasperated by stent prevention of vessel elasticity.2 Whether from blood clot formation
(thrombosis) around the stent or extended scar tissue formation (neointimal hyperplasia),
the result is a vessel that becomes once again occluded. The process of neointimal
hyperplasia can be seen as analogous to keloid formation in epithelial wounds,3 in which
scar tissues form without the standard checkpoints to finish proliferation. Both healthy
and diseased arterial cross-sections can be seen in Figure 3.1, with special focus to impact
of lumen diameter as a result of plaque in atherosclerotic vessels. Cell migration forming
restenosis causes similar results around the implanted stent.
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Figure 3.1 A) Normal, healthy artery showing fully open lumen. B) Plaque buildup
decreasing lumen diameter.4

Figure 3.2 A) Cross section of an artery showing vessel wall layers. 1. Intimal lined by
endothelial cells. 2. Intimal elastic lamina. 3. Media containing smooth muscle cells. 4.
External elastic lamina. 5. Adventitia with vasa vasorum & nervi vasorum.5 B) Migration
of smooth muscle cells into the tunica intima.3
Within a complex blood vessel, a number of cell lines come into play, each taking
up residence within varying layers of the vessel wall. In general, vessels may be broken
up into three categories based upon physiologic structure: arteries, veins, and capillaries.
For this study and disease, the focus will be on arteries, which exhibit high VSMC
control and dependence. As seen in Figure 3.2 above, a typical arterial wall is made up of
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three layers: the tunica externa (also known as adventitia), the tunica media, and the
tunica intima. In healthy tissue, the bulk of the tunica intima is comprised of (squamous)
endothelial cells, while the bulk of the tunica media is comprised of vascular smooth
muscle cells. (VSMCs).6 This first, interior layer creates a smooth, non-thrombogenic
surface for efficient blood flow without clotting. As mentioned in a previous section,
natural presence of heparin along these vessel walls prevents clotting and thrombosis
formation. Under injury this may be disrupted, allowing clot formation. A main cell of
our focus will be VSMCs, present in abundance in the tunica media and the main culprit
in excessive migration and proliferation leading to neointimal hyperplasia, seen in Figure
3.2. Residing in the tunica media with extracellular matrix (ECM), VSMCs may ‘spill’
out following injury to the endothelial layer.
Other cell lines of interest within vessels include fibroblasts and endothelial cells.
Fibroblasts, important in vessels for their role in angiogenesis,7 provide a beneficial
control group for cell effects, as they are hardy, easy to culture, and may contribute to
restenosis. Endothelial cells further help characterize the full effects of heparin-loaded
nanoparticles, being one of the first cell types intravascular drugs come into contact with
within a blood vessel. Furthermore, endothelial cells are originally disrupted by stent
implantation, an irritant potentially leading to restenosis. With stent implantation,
endothelial cells may be shielded from necessary shear stresses, aggravating the healing
process.8,9 For treatment of neointimal hyperplasia, the goal is to reduce vascular smooth
muscle cell proliferation and migration into the lumen and allow for healing
endothelialzation of the intima layer.
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Currently, a number of treatment methods exist for the treatment of neointimal
hyperplasia. Some within clinical use and others still in research and development,
treatment strategies under investigation include drug-coated angioplasty balloons, drugeluting stents as both preventative and direct treatment, intravascular brachytherapy,
systemic low-dose low molecular weight heparin (LMWH), and systemic low-dose
warfarin.3 Unfortunately, none of these therapy options are without drawbacks, creating
no perfect, one-size-fits-all treatment option for neointimal hyperplasia. While recent
advancements in angioplasty procedures have greatly reduced the prevalence of
restenosis, even the best preventative measures result in an estimated 5-10% restenosis,
largely by neointimal hyperplasia.10 Given the large number of PCIs performed every
year in the US alone, this corresponds to an alarming number of failed attempts at vessel
blockage removal.

3.2 Vascular Smooth Muscle Cells and Neointimal Hyperplasia
A main focus of review for this study, VSMCs are one of the key cell lines within
blood vessels and the most problematic cell line during neointimal hyperplasia. VSMCs
typically operate within our bodies under involuntary muscle control, contracting and
relaxing to alter luminal diameter and maintain appropriate blood pressure.11 VSMCs also
play roles in long term remodeling of blood vessels, changing cell number, and
synthesizing ECM to fit vessel needs.11 This function is performed by an induced change
in phenotype to the VSMC, a relatively unique feature among cells.12 Following vessel
wall damage, such as be stent or angioplasty, VSMCs work to heal and remodel the
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damaged area. VSMCs may further be influenced in cases where remodeling is affected
by stenting.13
For this remodeling and other normal functions, VSMCs operate under two main
phenotypes, which can be simplified as proliferating and non-proliferating for our
application. Key differences in these phenotypes are demonstrated in Figure 3.3. In
normal conditions, VSMCs primarily function to contract and regulate the lumen
diameter.14 This contractive action leaves the VSMC within a contractile phenotype,
which may be witnessed by the makeup and structure of the VSMC cytoskeleton. For this
contractive mechanism, the VSMC cytoskeleton is largely made up of three active fibers:
actin filaments, microtubules, and intermediate filaments.15 Actin filaments, a structural
component in many cells, respond to external forces and help mitigate cell migration.15
These fibers may be useful for imaging to determine overall structure and alignment of
the cell.
While within the contractile phenotype, these actin filaments are easily seen,
elongating the cell. In contrast, VSMCs within the proliferating phenotype have more
organelles in the cytoplasm, which allow the cell to be more proliferative.16 In imaging,
these changes may be qualitatively determined by comparing morphological differences.
As seen in Figure 3.3 below, the contractile phenotype presents itself as elongated and
spindle shaped while the synthetic phenotype appears to be more evenly stretched out.
Upon injury and denudation of the endothelial layer, smooth muscle cells become
exposed to a series of growth factors and inflammatory mediators released by
macrophages.16 In response, the cells may de-differentiate out of the contractile
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phenotype and migrate into the intima. Excessive migration and proliferation here may
lead to neointimal hyperplasia, occlusion of the vessel, and restenosis.

Figure 3.3 Diagram showing VSMC phenotype differences. The synthetic, noncontractile phenotype is seen on the left. The contractile phenotype is seen on the right.17
3.3 Treatment Methods of Neointimal Hyperplasia
To date, the majority of focus for arterial blockages has been towards clearance of
atherosclerosis or plaque build up. Because many treatment methods have proven
effectiveness in lumen diameter increases, innovation has been largely driven by
occurrence of restenosis. Initial treatments by balloon angioplasty and bare metal stents
(BMS) boasted the lowest rates, typically between 20-40% restenosis overall, with BMSs
slightly below that of balloon angioplasty alone.12 Still, these techniques showed as much
as 60% restenosis in high-risk patients.12 Balloon angioplasty, while relatively simple, did
little to prevent elastic recoil of the vessel, leading to popular use of angioplasty with
stents.18 Stents worked to hold the vessel open following angioplasty procedures, but also
posed new problems. Though clearing the vessel of blockage from original plaque
buildup, stents were prone to thrombosis and neointimal hyperplasia, leading to
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restenosis. This resulted in a newly blocked vessel and/or long-term anticoagulant drug
use.
No longer dealing with plaque blockages, much of treatment technique research
has explored preventative therapy for both causes of restenosis. Much of thrombosis
prevention relies on antiplatelet therapies systemically administered throughout the body.
To reduce the use of systemic drug administration, current research seeks to pair
currently used and approved atherosclerosis medical devices with other clinically used
drugs for early and local administration of drugs. Many solutions have been proposed,
including by drug-eluting porous balloons and drug-eluting stents (DES). Though
improving rates of restenosis, DESs do require prolonged use of antiplatelet therapies and
as such cannot be used on all patients.19
DESs are comprised of 3 main components, a metallic platform, a drug-carrier
vehicle for controlled delivery, and an effective drug.10 Many variations on stent
structure, coating release mechanism, and therapeutic agent, though the basic concept is
the same. DESs seek to provide homogenous drug delivery by releasing drug directly into
the tissue at controlled rates. These drugs seek to inhibit smooth muscle cell proliferation
and promote endothelialzation of the intima, speeding the healing process. Among a wide
variety of drugs in research and use, Sirolimus and Paclitaxel have shown to be the most
effective.10 Safety and effectiveness of DESs have been widespread, with only 5-10%
restenosis in both clinical trials and use.10,20 However, given the high volume of stent
implants, motivation for further reduction of restenosis rates is still high. Restenosis
following DESs comes from one of many sources: proximal end restenosis, resistant cell
lines, mechanical and drug release failures, hypersensitivity, and late restenosis.21,22,23
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Proximal end restenosis comes as a result of nonhomogeneous drug distribution to
the proximal end of the stent placement.10 At this end, drug distribution is less effective,
though angioplasty and stenting still cause irritation. Additionally, stent disruption of
laminar blood flow may reduce the shear stress environment necessary for proper
endothelial phenotype.8,9 Studies have shown that nonhomogeneous drug distribution
may put patients at higher risk for restenosis to develop.10,21 A number of stent designs
exist, though it has been found that closed, multicellular stent designs tend to offer the
most homogeneous drug delivery.10 However, many factors may play into
nonhomogeneous drug distribution including lack of full mechanical opening and contact
with walls, polymer damage, and blood flow alterations.21 These flaws may produce focal
areas at higher risk for restenosis.24,25,26
As mentioned previously, DESs work by controlled release of the drug over
specified time frames. Many commercial stents release drugs across weeks or months.10
However, with this model, late restenosis may occur once the drug has become fully
distributed,21 as has been seen in clinical use.10 In some rare cases, drug therapies may
additionally be ineffective in prevention. This included both resistant and hypersensitive
cell lines.21,22 With these failure modes, the need for post-stent restenosis therapy remains
high.

3.4 Endothelial Cells and Fibroblasts
Providing the smooth wall for blood flow within a vessel, endothelial cells make
up the tunica intima in a healthy vessel as a thin, single sheet of cells.27 These cells line
the entire vascular system, mediating the responses that control vessel dilation.27 They
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further provide an anticoagulant barrier between blood and the vessel wall.28 Necessary
for some many critical functions within the vessel, any injury to the endothelial cell layer
may result in severe consequences, including atherosclerosis, loss of membrane function,
and thrombosis.28 Within neointimal hyperplasia, this endothelial layer becomes
disrupted, allowing VSMCs to migrate into the intima. To hinder this migration, reendothelialization is required, providing the needed barrier between VSMCs and the
chemotactic factors.
Much like past simplifications of endothelial layers as only a hemostatic barrier,
much of past research has considered fibroblasts within the adventitia to serve solely as a
structural support member. However, within the past couple of decades, fibroblasts have
seen more consideration for potential roles in vascular disease. Observation of fibroblasts
has noted increased activation of adventitial cells with medial disruption following
endoluminal injury.29,30 This has led to the belief that these vessel injuries, including
those produced by stent and angioplasty procedures, may release substances activating
fibroblasts within the adventitia.31 Some findings further suggest that this activation may
trigger stimulation of cell migration and proliferation from increased releases of
paracrines.32 Under these assumptions, it may be possible that both smooth muscle cells
and fibroblasts migrate to contribute to neointimal formations, though currently these
mechanisms and proportions are only beginning to be understood.33,34 Further studies
have confirmed this phenomenon by neointima formation following adventitial damage.
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3.5 Conclusions
With so many unwanted side effects and the still-high prevalence of restenosis by
neointimal hyperplasia, we feel that development of a targeted drug therapy to inhibit
proliferation of VSMCs is needed. While DESs have improved preventive care, magnetic
targeted drugs could one day help eliminate those cases where DESs are not effective.
For such a treatment, many factors must be taken into account. We have proposed some
of the first of these factors to include preliminary studies on drug efficacy, in vitro
cellular effects, and magnetic targeting capabilities. By looking into the various cell types
to be encountered within a vessel, design an iteration of such a drug and carrier
nanoparticle system may be more effectively designed for trial.
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CHAPTER FOUR
SYNTHESIS AND CHARACTERIZATION OF HEPARIN COATED MAGNETIC
NANOPARTICLES

4.1 Abstract
Purpose: As discussed in previous chapters, magnetic nanoparticles show great potential
for targeted drug therapies. Size control, superparamagnetic properties, and
biocompatibility make magnetite nanoparticles a strong candidate for this application.
Heparin has been chosen for coating of these particles to improve biocompatibility and
reduce proliferation of vascular smooth muscle cells, the main source for neointimal
hyperplasia. Heparin, having anticoagulant properties would also provide benefits for
reducing thrombus formation, another factor in restenosis. This first portion of the study
focuses on synthesis and characterization of heparin-coated magnetic nanoparticles.
Materials and Methods: Magnetite nanoparticles were previously created in our lab using
thermal decomposition of iron acetylacetonate and oleic acid. Poly (ethylene glycol)
provided steric hindrance to stabilize particle and prepare for terminal ligand exchanges.
Terminal groups were exchanged for an amine group and then modified by attaching
heparin. Final particles were characterized by TEM, FTIR, DLS, Zeta potential, DMMB
assays, and Iron Concentration Assays.
Results: Characterization of the particles showed complete synthesis. Using TEM and
DLS imaging, we were able to confirm addition of polymer to raw nanoparticles. FTIR
confirmed addition of an amine group as the terminal group. Zeta potential showing a
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negative increase demonstrated the addition of heparin, which was further confirmed and
quantified by DMMB assays.
Conclusions: The initial results by our lab indicated the successful synthesis of heparincoated nanoparticles. Further batches have revealed further successful attachment of
heparin to the nanoparticles, but with variability among batches. This would suggest that
the process requires further refinement to reduce batch-dependent heparin loading.

4.2 Introduction
The following work includes combined methods and results for work conducted
by both this study and previous efforts within our lab, allowing for full characterization
and applicable conclusions over larger trials and batches of nanoparticle synthesis. Some
experimental portions have been conducted by a former lab partner, Elliot Mappus1 and
are edited for content for the inclusion of data in this study. This will allow a more
complete view of particle synthesis history for comparison and analysis. A main goal of
this study was to validate previously found results and show repeatability for entire
synthesis shown within Mappus’ thesis.1 Magnetic nanoparticles, as discussed at length
in previous chapters, have become much more common within industry and research,
allowing for a variety of synthesis methods. We have chosen to follow a modified version
of Sun’s thermodecomposition synthesis method2 for all batches, in keeping consistent
with prior lab practices. These nanoparticles were previously synthesized in bulk
quantities and provided by Clemson’s Mefford Lab, though the general procedure will be
outlined below.
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Many other varieties of synthesis for magnetic iron oxide nanoparticles exist, all
focusing on the production of particles with high magnetic saturation, stability,
biocompatibility, and an interactive surface for surface modification.3 Successful
methods have been reported using co-precipitation, thermal decomposition, hydrothermal
synthesis, microemulsion, sonochemical synthesis, sonochemical synthetic routes,
electrochemical synthesis, laser pyrolysis techniques, microorganism or bacterial
synthesis, and others.3 Wu, et al.3 summarizes many of these methods, listing coprecipitation as the most conventional. This summarization study further addresses
thermodecomposition for synthesis, the route we have chosen to take. This method allows
for mass production of particles within our target size range. The main disadvantage to
this method is that the resulting nanoparticles are left dissolved in nonpolar solvents,
which we are able to overcome prior to cell testing through the particle modification
process. Thermodecomposition further allows collection of nanoparticles with a
monodisperse size and shape, useful for biomedical applications.4,5
We have selected magnetite particles for use with core diameter of 20-25nm, near
the upper end of a critical size required for most applications.6 During bulk synthesis of
nanoparticles, a variety of sizes was created (as is typical for thermodecomposition) and
separated, allowing us to forgo struggling with parameters to control nanoparticle sizespecific synthesis. Magnetite was chosen based upon increased stability and
biocompatibility, as discussed in previous chapters.6,7,8,9 This chosen size, as discussed at
length in Chapter 2, is of utmost importance to the final properties of our particles to
avoid rapid filtration from the blood and also insure cellular uptake. It should be noted
that for our application, the first liver and kidney pass is of less importance as the future
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intended use would rely on catheter and magnetic targeting of disease sites rather than
systemic delivery. In addition, as also discussed in Chapter 2, particles should fall within
an optimal range to exhibit single-domain, superparamagnetic properties, thus lowering
the magnetic moments and tendency to agglomerate. Literature has found the ideal range
for magnetite to be 5-20 nm diameter.6 In general, magnetic particles have a magnetic
force between them proportional to size, making smaller particles more desirable for
stability in solution. In using particles of this size and material, stability and
biocompatibility can be maximized.
Stability of our particles comes as a result of three stability strategies. The first,
discussed above, comes from the small magnitude of magnetic force between particles
outside of an external magnetic field. Reducing size of our particles helps minimize these
effects. Stability may also be gained through steric hindrance, typically accomplished in
nanoparticles with surface coatings. Common mechanisms include use of surfactants,10
polymers,11,12 silica,13 carbon,14 or precious metals.15 We have chosen to use
poly(ethylene glycol), one of the more studied polymers. This allows increased stability
by steric hindrance as well as potential for further surface modification, including the
addition of heparin. One final mechanism for stability is by electrostatic repulsion. The
addition of heparin helps further achieve this stability, utilizing the strong negative
charge on heparin. This addition of heparin further couples a clinically established drug
with a targeted drug delivery system for localized drug delivery to the site.
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4.3 Materials and Methods
Raw Particle Synthesis
Magnetite nanoparticles were synthesized using iron (III) acetlyacetonate
(Fe(acac)3) (Fluka) as the iron precursor and oleic acid (Alfa Aesar) as the ligand using a
1:15 molar ratio. This allowed us to follow identical protocol to that developed
previously in collaboration between Clemson’s Dean and Mefford Labs, following a
modified Sun’s thermodecomposition synthesis method.2 Particles were bulk synthesized
in a variety of sizes and characterized using Transmission Electron Microscopy (TEM).
Based upon prior lab work and literature; 25 nm diameter particles were selected for the
continued modification. See appendices for full protocol for synthesis of raw magnetite
(Fe3O4) nanoparticles.

Ligand Exchange
The hydrophobicity of the raw particle (with oleic acid coating) synthesis is one
of the main hindrances to the testing of raw particles directly with cells. These particles
were left suspended in Tetrahydrofuran (THF) for storage, which though relatively
nontoxic for organic solvents, would cause undesired adverse effects on cell lines in
administration. To further develop and stabilize the particles for cell administration and
prepare them for drug attachment, an intermediate ligand exchange must occur. This was
accomplished by attaching a hydrophilic polymer of nitroDOPA anchors attached to
1,800 g/mol poly (acrylic acid) (Sigma-Aldrich) with a 8,000 g/mol poly (ethylene
glycol) (Sigma-Aldrich) spacer terminated in an alcohol. See Figure 4.1 for chemical
structure of this polymer. For this ligand exchange to occur, nanoparticles were dried of
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THF by rotary evaporation and suspended in 5mL of chloroform. Excess of the
previously described polymer (~250mg) was dissolved in chloroform (5mL) (Fisher
Scientific) to insure complete coverage. The nanoparticle-chloroform solution was then
added drop-wise to the excess polymer under a nitrogen blanket and sonication over a
period of 15min. Following full delivery of particles, the entire solution was agitated
under sonication for 24 hours and purified in a THF GPC column to remove the
unreacted polymer. Rotary evaporation was used to remove THF, allowing storage in
water for future dynamic light scattering (DLS) and zeta-potential analysis. This full
ligand exchange process results in our desired change from hydrophobic to hydrophilic,
utilizing the alcohol terminal group. This step sets up the nanoparticle to accept the
desired drug coating. For full protocol, please see the appendices.
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Figure 4.1 PEG polymer used in ligand exchange to stabilize the nanoparticle via steric
interactions and improve biocompatibility.1

Modification with Heparin
Before the attachment of the desired drug, heparin in this case, a secondary
polymer modification is required. This step aims to change the nitraDOPA terminal
groups to an amine. To first prepare for reaction, particles were dried of solvent to a
powder by freeze-drying and suspended in dichloromethane (DCM) (Acros Organics).
Under a nitrogen gas blanket, Triethylamine (Fisher Scientific) and 3-chloropropylamine
(Sigma) in a 1:3 molar ratio were dissolved in 5mL of DCM. This was conducted with 3chloropropylamine in excess to insure coverage, while Triethylamine provided protection
as an acid scavenger. The nanoparticles were once again added drop-wise to the DCM
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solution and then agitated under sonication for 48 hours. To remove excess
chloropropylamine, ether was added and the solution was centrifuged for 10min at
10,000rpm. This was then dried in a vacuum oven without heat to remove the ether and
freeze-dried of excess DCM to a powder. The nanoparticle powder was then suspended in
water for determination of iron concentration and preparation for heparin loading.
To finalize the heparin attachment, EDC/NHS chemistry was used to bond
carboxylic acid groups of heparin to the amine groups of the nanoparticles. This process
makes standard use of (1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide) (EDC) as a
crosslinking agent to couple carboxylic acid groups to primary amine groups. To increase
stability of the resulting active ester, N-hydroxysulfoxuccinimide (sulfo-NHS) was
added. First, nanoparticle concentration was calculated using an iron determination assay
as explained in the appendices. This allowed calculation of coated nanoparticle
concentration and an estimation of total free ligands. To account for error in estimation of
nanoparticle-ligand coverage, 3 times excess heparin was used to further insure full
coverage. Molar ratios were dissolved in deionized water of 1 ligand: 3 heparin of
molecular weight 3000g/mol (MP Biomedicals) : 30 EDC (TGI) : 65 sulfo-NHS (Thermo
Scientific). The latter three components were combined and allowed to equilibrate for
15min, followed with addition of the nanoparticle/ligand. After 24 hours of reaction (as
opposed to 12 hours in previous batches), the resulting heparin-coated nanoparticles were
purified in a water column to remove the excess heparin and reactants. A summarization
of the particle synthesis is provided in Figure 4.2. The proposed heparin-coated
nanoparticle can be seen in Figure 4.3.
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Figure 4.2 Chemical synthesis mechanisms for heparin coated magnetite nanoparticle.1
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Figure 4.3 Proposed synthesized heparin nanoparticle.1

Particle Characterization
For initial particle size selection, transmission electron microscopy (TEM),
conducted and summarized by Elliot Mappus1 was used to measure the size distribution.
Diluted (~0.1mg Fe3O4 per mL) hexane solution was dropped onto a copper grid coated
with a carbon film. Using a Hitachi H-9500 instrument with an accelerating voltage of
300 kV, high-resolution images were obtained at 200,000X and 600,000X. Using Feret’s
diameter function from ImageJ’s particle analysis, approximately 300 nanoparticles were
measured to determine size distribution. Before and after the addition of the terminal
amine, Fourier transform infrared spectra (FTIR) was taken by Thermo-Nicolet Magna
550 FTIR to confirm the presence of a primary amine with peaks of 1580-1650 cm-1 and
3320-3520 cm-1.1
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Each step of the process from raw nanoparticle to heparin-coated nanoparticle
was analyzed using dynamic light scattering (DLS), Zeta-potential, and visual inspection
of color to confirm purity and presence of iron, particle size growth, and surface charge.
This allowed further characterization of the particles, confirmation of heparin loading,
and confirmation of results with previous work conducted within our lab. DLS
measurements made using a Malvern Zetasizer NanoZS allowed monitoring of the
particle hydrodynamic diameter once dissolved in deionized water and confirmation of
particle growth following ligand exchange and heparin modification. Intensity-weighted
sizes are reported.
Additionally, a comparison of Zeta-potential, analyzed using capillary cell
electrophoresis technique and the same system as DLS, between the post-ligand exchange
particles and final heparin-loaded particles gave a rough confirmation of presence of
heparin on the particles due to the increase in negative Zeta-potential. Zeta potential
measures the electric potential at a small distance from the surface of the particle relative
to a point far away in solution. This can be simplified as the potential difference between
electrostatically bound fluid and dispersive fluid.1 Visual inspection and iron
concentration assays throughout confirmed these changes in hydrodynamic diameter and
zeta potential to be accounted for by particles and not just excess reactants.
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Figure 4.4 Schematic of ions away from a particle and resulting electrical
potential as a function of distance from the particle surface.1 Taken from
http://en.wikipedia.org/wiki/Zeta_potential and reproduced in accordance to CC BY-SA
3.06
Iron Determination Assay
As discussed above, knowing the iron concentration at various stages of particle
synthesis is critical for calculation of reactant amounts and final nanoparticle
concentration to be used for administration to cell lines. Each step of the particle
synthesis involves loss of particles and gain of solvent, thus requiring repeated running of
the iron determination assay at many checkpoints along the synthesis. This modified
method16 can be found in full in the appendices. In short, working solutions of
Hydroxylamine hydrochloride, 1,10-phenanthroline, and ammonium acetate were used to
generate color change as a function of iron presence. This was compared to a previously
generated standard curve. Absorbance was read at 690 nm for background and subtracted
from absorbance at 511 nm using a UV/Vis spectrophotometer. These values were
62

analyzed against a previously generated standard curve and allowed calculation of
nanoparticle concentrations using particle diameter from TEM analysis (25 nm), density
of magnetite (5.2 g/cm3),17 and volume of solution.

Dimethyl Methylene Blue Assay
Once nanoparticle solution concentration is known, heparin loading must be
assessed. This assay uses a modified method18,19 to quantify heparin loading per
nanoparticle. For this assay, 1,9-dimethymethylene (DMMB) (Sigma) is used to undergo
a shift in absorption spectrum when bound to sulfated glycosaminoglycans (GAGs). We
first generated a standard curve comparing chondroitin sulfate to heparin as GAGs for
DMMB absorption shift, finding them not significantly different. This allowed
quantification of heparin attached to nanoparticles using nanoparticle solutions as the
GAG component. For full protocol, please see the appendices.

4.4 Results

Figure 4.5 Left) Histogram of nanoparticle magnetic core diameter distribution.1 Right)
TEM image of uncoated iron oxide particles.1
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TEM imaging shows particles to be synthesized in a uniform distribution with
average diameter of 24.3 +/- 1.9 nm. Hydrodynamic diameter measuring of these
particles estimated a diameter average of 64.43 nm. Following initial polymeric addition
of nitroDOPA, the hydrodynamic diameter notably increased to 150.1 nm. Following
terminal group changes to a primary amine group, hydrodynamic diameter decreased to
149.1 nm. Finally, after addition of heparin, we saw a further drop of hydrodynamic
diameter to 131.6 nm. Figure 4.6 summarizes these findings according to intensity
measurements. DLS of following batches also exhibited this normal distribution shape.

Figure 4.6 Dynamic light scattering showing hydrodynamic diameters of particles for the
pilot batch containing heparin loading at 2.889 ug heparin per ug nanoparticle.1
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Functional Group
Fe3O4
NP-OH
NP-NH2
NP-Hep

Pilot Batch
Hydrodynamic
Zeta-Potential
Diameter/Z-Avg.
(mV)
(nm)

64.43
150.1
149.1
131.6

-**
-0.809
1.07
-3.74

Final Scale Up
Hydrodynamic
Zeta-Potential
Diameter/Z-Avg.
(mV)
(nm)

-*
91.9
103.7

-**
-10.6
-22.7

Table 4.1 Summary of hydrodynamic diameter and zeta potential following each step in
particle synthesis. Heparin Loading of each batch was found to be 2.889 and 2.956 ug
heparin per ug nanoparticles *The same raw particles were used for each batch.
respectively.1 **Note, raw magnetite nanoparticles were not suspended in water, thus
zeta potential was not measured.
To confirm results seen by particle growth with DLS, FTIR was conducted
following amine addition. The primary amines may be seen by a small to medium peak
with a wavenumber in the range of 1580-1650 cm-1 as well as 3320-3520cm-1, both
circled in Figure 4.7.20 This coupled with DLS particle size changes suggests successful
amine addition.1
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Figure 4.7 FTIR Spectrum after addition of terminal amine group to polymer.1

Following hydrodynamic diameter measurements, we analyzed the zeta potential
of each step in synthesis once suspended in dH20. Pilot batch PEGylated nanoparticles
were found to have a zeta potential close to zero of -0.809 mV, consistent with PEG
coated particles from literature.21 Following amine terminal group addition, zeta potential
increased to 1.07mV. Heparin attachment via EDC/NHS chemistry led to a zeta potential
drop to -3.74mV. These results were found to be consistent with similarly modified
nanoparticles.21,22,23 Other studies with heparin-coated nanoparticles have also reported
more negative zeta potentials, ranging between -10 and -40 mV.24,25 This was witnessed
in our upscale batch with a final zeta potential of -22.7 mV. This helped confirm results
from DMMB of successful heparin loading. These results are summarized in Table 4.1
for comparison of synthesis step, hydrodynamic diameter, and resulting zeta potential.
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Following attachment of heparin, resulting product was purified using a water
column. The output for this was collected in 5mL fractions. Fractions with suggested
nanoparticle content were determined by the presence of a brown color tint.1 All fractions
were analyzed by DMMB assay to assess GAG concentration. Fractions 3-9
demonstrated nanoparticle content and were further analyzed using iron determination
and DMMB assays to confirm heparin loading and successful particle purification.
Purification results can be seen in Figure 4.8. The distinctive bimodal distribution
indicates both successful attachment of heparin and completed purification of the
nanoparticle. Fractions 3-9 correlate to a spike in GAG concentration as well as solution
tinting from iron content. Excess heparin removal is seen above fraction 9 by the increase
in GAG concentration.

Figure 4.8 Purification profile of heparin nanoparticles, measured with DMMB assay
following water column purification.1
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Theoretical loading of heparin per nanoparticle was calculated using diameter
from TEM analysis and the assumption of 5 free ligands/nm2. This value was determined
to be approximately 1.2 g of heparin per gram of nanoparticle, or approximately 9400
heparin molecules/nanoparticle. The actual loading was determined using the previously
described iron concentration assay and DMMB assay. Figure 4.9 illustrates the actual
heparin loading as determined by the DMMB assay for five batches of nanoparticles. The
initial batch showed high heparin loading with 2.889 µg heparin per µg nanoparticle, or
approximately 22, 500 heparin molecules per nanoparticle. Initial attempts at batch upscaling reduced heparin loading, showing only 0.976 µg heparin per µg nanoparticles, or
approximately 7,600 heparin molecules per nanoparticle. Adjustment of excess
proportions yielded a final batch of nanoparticles (used in future cell studies) with 2.956
µg heparin per µg nanoparticle, or approximately 22,590 heparin molecules per
nanoparticle. This is further validated by DMMB analysis of amine-terminated particles,
showing very low absorbance.

68

Figure 4.9 Determination of heparin loading on nanoparticles by iron
concentration and DMMB assays.1
4.5 Discussion
TEM imaging demonstrated our particles to be within target size for the desired
application. As discussed previously, magnetic nanoparticles must be sufficiently small to
maintain single-domain, superparamagnetic (SPM) properties. Although further testing of
magnetic capabilities is required, TEM imaging would suggest that these particles are
small enough to exhibit these properties. Previous studies conducted within our lab have
predicted ideal nanoparticle diameters to be between 20 and 30 nm,1 which we have
reached. In vivo or simulated studies on the magnetic properties of these particles will be
required to determine magnetic saturation and targeting capabilities. Though the small
size of these particles would suggest potential SPM properties, large polymeric coatings
may increase drag within solutions or blood vessels, requiring stronger magnetic fields.
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These coatings further enhance the stability of the particles in solution, which may allow
some deviation from SPM to ferromagnetic properties.
Previously we have discussed other concerns for size-dependent properties of
nanoparticles. Many of these factors consider size parameters within the body and the
effect on elimination via filtration.26,27,28,29 However, for this application, the primary
concerns should be considered as a combination of magnetic properties and
pharmaceutical efficacy. Many drugs attached in bulk to nanoparticles will result in final
particles larger than the standard ceiling for rapid liver filtration. Fortunately, with
targeting technology via magnetic controls, this rapid filtration may be a potential benefit
in reduction of undesired, adverse effects following administration.
There was a noted, significant difference between particle diameters according to
TEM versus DLS. DLS shows size within the solution, while TEM shows dried particles.
Because of this and bias towards larger particles,30 DLS may show larger diameters than
expected. Within solution, particles may expand beyond dried state and may have a
tendency to agglomerate. This further shows necessity for the addition of polymeric
coatings to provide stability within solution to maintain particle size. Thus, we have
determined TEM to show the primary particle size for our nanoparticle core. DLS
demonstrates the need for stability as well as assurance of particle size growth following
chemical reactions. Some evidence would suggest TEM images are more likely to be
skewed as being larger than real, as the eye is drawn to larger particles for counting.30
The initial study within our lab conducted several batches of heparin-loaded
nanoparticles. We were able to successfully track size growth and surface charge of these
particles, confirming addition of each step in synthesis of the particles. Observed size-
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changes following each step confirm addition of the initial polymer growth and terminal
group changes. Similarly, zeta potential drop with the addition of heparin suggested
successful attachment. The pilot batch zeta potential confirms heparin loading, though at
less negative values compared to literature.24,25 This may be due in part to the
polyethylenimine coating prior to heparin addition with some unbound positive surface
charges.24 However, the final upscale batch demonstrated more complete heparin loading,
giving zeta potential values more consistent with literature. This was further confirmed
with DMMB assays, allowing quantification of heparin loading per nanoparticle. In the
initial batches, a wide range of variability was seen between the initial pilot batch and
early upscale attempts. Further controls on heparin addition, by adjustment of excess
calculations and reaction time, led to higher heparin loading for bulk synthesis, as was
originally seen in the pilot batch.
A purification profile was further used to verify heparin attachment and removal from
solution. Heparin left in solution with the particles would skew loading results from
DMMB assays, thus necessitating purification by GPC columns. The curve above
demonstrates the bimodal distribution shape of heparin content by fraction of water
collected. The initial spike suggests the heparin attachment to nanoparticles, further
confirmed by iron determination assays. Later spiking suggests excess heparin has been
separated and filtered from the nanoparticles.
Using both the Iron Determination and DMMB assays, we were able to quantify
average heparin loading per nanoparticle. The initial batch yielded a heparin loading of
2.889 µg heparin/µg nanoparticle. With initial attempts for upscale using the same
synthesis proportions, heparin loading was only found to be between 0.831 and 0.976 µg
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heparin/µg nanoparticle, as seen by the slopes from the curves in Figure 4.9 above.1
Previous studies have suggested that this may be due to heparin’s natural electrostatic
repulsion against itself at pH values greater than 3.1,31 Because of this, increased heparin
concentrations may have prevented some attachment within the same reaction time. Thus,
allowing more reaction time as compared to initial batches may have contributed to
higher heparin loading. However, this very self-repulsive property also proves to be
beneficial for stability and shelf life within solution. The DMMB assay was further
conducted on amine-terminated particles to validate the assay for heparin content rather
than nanoparticle content. Low absorbance within the spectrum demonstrates low GAG
content and validity of the assay. The small amount of GAG content may be noise from
nanoparticle iron colors.
This 3-fold difference in heparin loading between samples was hypothesized to hold
great effects on the preliminary cell testing, as each nanoparticle entering the cell would
hold more or less heparin depending on batch. Adjustment of heparin allowed a new,
bulk-scale batch with 2.956 µg heparin / µg nanoparticle. This final batch was used for
cell experiments within this study and compared to results found from the previous two
batches. Results were largely found to be similar, though with a lower effective dose
corresponding to higher heparin loading. This is to be expected as more heparin enters
the cell with each particle. Future studies will utilize only updated particle synthesis
procedures, insuring high heparin loading.
The next chapter discusses preliminary results of cell studies utilizing these finished
particles. To create a system of controls, some particles were left with the terminal amine
particle, prior to the addition of heparin. For cell studies, this was used as the control
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particle, as raw nanoparticles synthesized by this method are inherently toxic to cells. Use
of oleic acid as the surfactant resulted in raw hydrophobic nanoparticle, kept in solution
with solvents that are incompatible with cell media. Coating with PEG, a commonly used
coating within the medical field,31 allowed us to dry the particles of toxic solvent,
ultimately replaced by water. This step additionally helps stabilize the particles, reducing
agglomeration witnessed by DLS of raw particles. Thus, the addition of PEG successfully
fulfilled many necessary requirements for the use of iron oxide nanoparticles in a
biologic environment.
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CHAPTER FIVE
EFFECTS OF HEPARIN-COATED MAGNETIC NANOPARTICLES
ON RELEVANT CELL LINES
5.1 Abstract
Purpose: Even with new advancements in stent and angioplasty technologies, restenosis
by neointimal hyperplasia is still a main concern of endovascular surgery. Stresses may
induce vascular smooth muscle cell (VSMC) phenotype change, migration, and
proliferation resulting in further occlusion of arteries post-treatment. The ability to
reverse this phenotype change, thus slowing proliferation, would allow vessel healing and
re-endotheliazation. In pursuit of this, we have developed heparin-coated magnetic
nanoparticles for targeted drug therapy of neointimal hyperplasia. This study describes in
vitro testing of these particles on relevant vascular cell lines.
Materials and Methods: VSMCs, Endothelial Cells, and Fibroblasts were treated with 0100ug/mL concentrations of heparin-coated magnetic nanoparticle solutions and
compared against control parameters. Initial cell uptake of particles was analyzed using
Prussian Blue Staining and TEM imaging. Cell proliferation and toxicity was measured
using MTS and Live/Dead assays. Immunofluorescence staining was used to evaluate
effects on cell phenotype.
Results: We observed inhibition of proliferation of VSMCs with doses as low as 1
µg/mL. Higher concentrations led to an increase in cytotoxicity. Fibroblasts showed less
strong of a reaction to nanoparticles. Endothelial cells showed an increase in proliferation
in response to heparin and heparin-coated nanoparticles. Preliminary results suggest
possible phenotype changes of VSMCs in response to heparin-coated nanoparticles.
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Conclusions: These preliminary results indicate potential for clinical use. Further
investigation is required to determine optimal dosing. Further characterization of VSMC
phenotype change is required. Further exploration into effects on endothelial cells is
required, as preliminary results showed a possibility for improving re-endothelialization
of vessel following injury.

5.2 Introduction
Predicted to explode in prevalence numbers over the next few decades,
atherosclerosis and cardiovascular disease (CVD) treatments continue to develop and
improve their efficacy. Unfortunately, many of these treatments result in adverse stresses
on cells and damage to the interior wall of the diseased blood vessels. Once the
endothelial layer becomes disrupted, vascular smooth muscle cells (VSMCs) may
migrate due to exposure to platelet-derived growth factors, chemokines, and other
mitogenic factors.1 The excess proliferation caused has led to a relatively high percentage
of angioplasty procedures resulting in restenosis, or the closing off of a vessel following
angioplasty and percutaneous coronary intervention (PCI). When cells, such as VSMCs
migrate and proliferate into the intima of the vessel, this is known as neointimal
hyperplasia. This new, damaged and diseased state exposes cells to alternative
environments, influencing phenotype changes and slowing the healing process.
Ordinarily within the tunica intima of a healthy artery, endothelial cells provide a
smooth lining for blood flow and a protective barrier against clot formation. When
disrupted by stresses and stent placement, gaps may open up allowing VSMCs to migrate
out. Regaining this protective cell wall requires endothelial cells to proliferate and re-coat
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the damaged area. However, fluid dynamics around the edges of stent placement have
shown a reduction of shear forces required for correct endothelial cell phenotype.2
Typically, it has been shown that these areas are problem areas for neointimal hyperplasia
and restenosis.2,3
VSMCs also undergo phenotype changes in response to this injury, resulting in
the opposite effect, or heightened proliferation. Under healthy conditions, VSMCs may
undergo phenotype changes to regulate lumen diameter and blood pressure. When
exposed to the new environment, VSMCs receive chemical signals to revert to the
proliferative phase rather than the contractile phase.

5.3 Materials and Methods
Cell Culture
For isolation and culture of each cell line, please refer to the appendices. Cell
lines chosen for relevance to vasculature included Rat Vascular Smooth Muscle Cells
(VSMCs), Porcine Endothelial Cells (PECs), and Rat 3T3 Fibroblasts (3T3s), all used
between passages 4-9 and 70-90% confluence. All cell culture media and control media
was created as complete cell media (CCM) containing High Glucose Dulbecco’s
Modified Eagle’s Medium (DMEM) (Gibco), 10% fetal bovine serum (FBS) (Atlanta
Biologicals), and 1% penicillin/streptomycin (AA) (HyClone). Standard incubation for
culture and experimental conditions was conducted at 37oC and 5% CO2.
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Nanoparticles and Experimental Conditions
Nanoparticles were synthesized according to the methods described in Chapter
Four. Final synthesized particles (NP-Hep) containing heparin on the surface were used
as the main experimental condition. For comparison of effectiveness and control
parameters, amine terminated particles (NP-NH2) solutions, raw heparin (MP
Biomedicals) solutions, and untreated cells were used as described in the various cell
assay procedures. NP-NH2 particles were synthesized as described in Chapter Four, but
were suspended in water without heparin modification such that the terminal group was
left as an amine. As also described in Chapter Four, the hydrophobicity of the raw
nanoparticles is not conducive to cell culture, thus these particles were not used as a
control group. As particles were synthesized outside of sterile conditions, filtration is
recommended to reduce risk of infection.
For experimental conditions, both sets of nanoparticles were used from bulk
solutions of 1, 10, 25, 50, and 100 µg/mL of nanoparticles in CCM. Heparin was used in
solution with CCM in concentrations of 1.56, 6.25, 25, 100, 400, 1600 µg/mL. These
studies utilized particles from the latest batch synthesis, averaging 2.956 µg heparin / µg
nanoparticle. Thus, our range of heparin-loaded nanoparticles demonstrates heparin
weight concentrations ranging from 2.956 µg/mL to 295.6 µg/mL. This allows
comparison across our lab studies for raw heparin as well as between raw heparin and
heparin-loaded nanoparticles.
Quantitative stability of our particles in solution is unknown, though particle size,
polymeric steric hindrance, and electronegative repulsion should prevent agglomeration
of particles in solution for short-term use. Over the duration of this study (several
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months), no agglomeration of the nanoparticles was witnessed. In the case of
agglomeration of older particles, solutions were decanted with magnetic assistance
(which holds to the larger particles, as discussed previously) and filtered. According to
the manufacturer (MP Biomedical), our heparin is stable within solutions of pH 4-9 at
refrigeration. As such, heparin concentrations were prepared in bulk for MTS and
Live/Dead assays. Nanoparticles were kept suspended in dH2O for long-term storage and
suspended in media within 2 weeks of use.

MTS Assay
With a main aim to study proliferation effects on cell lines, the CellTiter 96®
Aqueous One Solution Cell Proliferation Assay MTS kit (Promega) was used. This kit is
a one-step colorimetric method that allows assessment of number of viable cells in
proliferation, cytotoxicity, and chemosensitivity. Viable cells reduce the MTS tetrazolium
compound,

[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-

sulfopheynl)-2H-tetrazolium], into a colored formazan product that can be read via a
microplate reader for quantification of cell viability. For this assay, cells were seeded at
2,000 cells/well suspended in standard CCM into a 96-well plate and incubated for 24
hours. Pending proper attachment, standard media was removed and replaced by the full
spectrum of nanoparticle solutions, heparin solutions, and controls consisting of cells
with standard media and cell-free wells with standard media. Experimental conditions
were then incubated for 48 hours. Following experimental incubation, cells were further
incubated for 2 hours in a 1:5 ratio of MTS Assay kit and CCM. Absorbance was read at
490 nm using a microplate reader and normalized against cell-free plates containing only

82

CCM and MTS to compensate for any color distortion caused by media. For full protocol,
see appendices.

Live/Dead Assay
The Live/Dead assay further helps confirm cytotoxicity of experimental particles.
For this assay, cells were seeded at 20,000 cells/well into a 24-well plate and allowed 72
hours to adhere and grow in the standard CCM. Following this 72-hour incubation
period, cells were checked to confirm confluence. Old media was aspirated and replaced
with the full spectrum of nanoparticle and heparin concentrations as outlined above. For
control conditions and analysis, control wells without nanoparticles were incubated in
fresh CCM. Cells were then incubated under standard incubation conditions for a further
48 hours. The Live/Dead Viability/Cytotoxicity kit (Life Technologies) was used to
create solutions of 2 µM calcein acetoxymethyl (2 µM C), 4 µM ethidium homodimer-1
(4 µM Etd-1), and 2 µM calcein acetoxymethyl with 4 µM ethdium homodimer-1 (2,4
µM C+Etd-1) solutions diluted in PBS and protected from light. All experimental
conditions were treated with 2,4 µM C+Etd-1 solution. Positive controls were treated
with all three solutions and negative controls, created with 70% ethanol, were treated
with 2 µM C and 4 µM Etd-1 solutions. All treated cells were incubated with Live/Dead
kit solutions for 30min and imaged using an EVOS fluorescent microscope for red/green
fluorescence. This was additional quantified using a microplate reader for fluorescence
from 485nm excitation to 530nm emission and 530nm excitation to 645nm emission. For
full protocol, see appendices.
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Short-Term Particle Uptake Analysis
Two protocols were used for determination of particle uptake by cells after a 2hour period of experimental conditions. The first utilized a Prussian Blue Stain kit
(Polysciences) and the second used TEM imaging to help confirmation of prior results
from the Prussian Blue Staining.
For both experiments, cells were seeded at 5,000 cells/well into a 96-well plate
and incubated in CCM for 24 hours. Pending confluence, media was replaced with
nanoparticle solutions in doubles at concentrations of 1, 10, and 50 µg/mL for both NP-H
and NP-NH2 particles. Control conditions were created using standard CCM. All cells
were incubated under experimental conditions for 2 hours and then fixed using 4%
Paraformaldehyde (PFA). At this point, cells were used for either the Prussian Blue Stain
or TEM imaging. The following will briefly overview the staining and imaging
procedures. For full protocol, please see the appendices.
For Prussian Blue Staining, the working solution reacts with iron particles to form
a blue-colored compound. This working solution was made of 4% potassium
ferrocyanide and 4% hydrochloric acid mixed in equal parts. Cells were stained with this
working solution and then counterstained with Nuclear Fast Red for 3 min. These cells
were then imaged using the Olympus CKX41 microscope.
To confirm results from Prussian Blue Staining, TEM imaging was attempted for
better imaging of the iron portion of the nanoparticles. Further discussion of TEM
methods and attempts are discussed at further length in the results and discussion
sections.
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Immunofluorescence Staining
Immunofluorescence staining was used for each cell type to analyze phenotypic
changes. Each cell type received similar treatment, differing in use of primary and
secondary antibodies. Cells were seeded at 2,000 cells/well into a 96 well plate and
allowed to grow for 24 hours in CCM. This media was then replaced for experimental
conditions in duplicates for nanoparticle concentrations of 1, 10, and 50 µg/mL. Control
groups consisted of cells in CCM. Cells were incubated in experimental conditions for 48
hours and then fixed with 4% paraformaldehyde (Sigma).
VSMCs were targeted for smooth muscle actin using Rabbit Polyclonal Primary
Antibody to Alpha Smooth Muscle Actin (Abcam) paired with Secondary Antibody
Donkey Anti-Rabbit (Abcam) to yield a green fluorescence on actin fibers. PECs were
targeted for VE-Cadherin using Mouse Monoclonal Primary Antibody to VE-Cadherin
(Santa Cruz Biotechnology) paired with Secondary Antibody Donkey Anti-Mouse
(Abcam) to yield a red fluorescence on cellular junctions. 3T3s were targeted for collagen
type 1 using Mouse Monoclonal Primary Antibody to Collagen Type 1 (Abcam) paired
with Secondary Antibody Donkey Anti-Mouse (Abcam) to yield a red fluorescence on
collagen. All cell types were further stained with (4’,6-diamidino-2-phenylindole)
(DAPI) for cell nucleus. Following stain, cells were imaged using an EVOS FL Imaging
System. See appendices for full staining protocol.
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Statistical Analysis
All experimental conditions are evaluated against the control parameters. MTS
and Live/Dead relative viabilities were tested using a Student t-test. Results were
considered significant for p < 0.05.

5.4 Results
Prussian Blue staining was used to determine uptake of particles following 2
hours of exposure. Close examination of cells treated with heparin-coated nanoparticles
contains areas of dark blue staining in vesicles, previously suggested as possible presence
of nanoparticles. Heparin-coated nanoparticles did not produce any phenotype changes
observable by phase contrast microscopy following 2-hour exposure. In the presence of
iron, solutions should present a blue color visible to the naked eye.4,5 This was not the
case, as much of the blue tint in pictures is likely due to the imaging technique/system.
This further led to assessment of the Prussian Blue working compound mixed directly
with 25 µg/mL nanoparticles in solution at a 5:1 ratio respectively. The results showed no
solution color change (images not shown) at the 10 min, 30 min, or 24 hours time marks.
Lack of certainty and clarity in these images led to attempted TEM imaging of cell
interiors. Due to difficulties, TEM imaging of cell interiors did not render valid results.
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Figure 5.1 Prior lab work of VSMCs with Prussian Blue Stain of various nanoparticle
concentrations. Images taken at 20x. Red arrows point to proposed nanoparticle
agglomerations.6

Figure 5.2 a-c) Reproduced Prussian Blue Staining of VSMCs. Picture d) shows cells
with no stain applied, demonstrating the blue color present without stain application.
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The MTS assay shows quantitative effects of experimental conditions on each cell
line in relation to dose. Based on morphology, seen in Figure 5.3, amine terminated
nanoparticles were found to result in widespread cell death at concentrations of 50 µg/mL
and higher. This is further evaluated using the Live/Dead assay, discussed below. At only
1 µg/mL, NP-Hep showed a significant decrease in VSMC proliferation. This was found
to be statistically significant with p-value = 0.0007. All concentrations of heparin-coated
nanoparticles were found to result in a statistically significant decrease (1 Tailed TTest
with p-value < 0.05) of relative cell viability when compared to control particles. Amine
terminated particles were only found to be statistically different at and above 50 µg/mL.
The same level of proliferation inhibition is not seen in heparin at any concentrations of
study and was not found to be significantly different than by control particles.
Fibroblasts visually showed a lessened effect on proliferation as compared to
VSMCs, though many concentrations were still found to have statistically different
means than the control. Amine-terminated nanoparticles significantly affected fibroblast
viability at 10 µg/mL and above. Heparin concentrations produced inconsistent results for
significance with no discernable trend.
Endothelial cells showed an interesting reversal of expected results, trending to
increased proliferation with exposure to all experimental groups. Raw heparin produced
significant increases in endothelial cell viability at most concentrations. Due to small
number of trials, statistical significance could not be determined for all concentrations of
heparin-coated nanoparticles.
Results are summarized in Figure 5.3 for proliferation in response to heparincoated nanoparticles, amine-terminated nanoparticles, and raw heparin solutions. All
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MTS

assay

results

are

evaluated

relative

to

control

wells,

or

0

µg/mL

nanoparticles/heparin. Control group average set to 100% viability with error for
variability among control groups. All other cell viability averages and error is relative to
this.

Figure 5.3 Compiled results of proliferation of each cell line as a function of heparincoated nanoparticle concentration.
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Concentration
VSMCs
Fibroblasts
Endothelial Cells
NP-Hep 1 ug/mL
0.0007
0.8256
0.0723
NP-Hep 10 ug/mL
0.0002
0.4869
0.0178
NP-Hep 25 ug/mL
0.0001
0.0464
0.2188
NP-Hep 50 ug/mL
0.0002
0.0021
0.8260
NP-Hep 100 ug/mL
0.0006
0.2286
0.0083
NP-NH2 1 ug/mL
0.3205
0.2102
0.0098
NP-NH2 10 ug/mL
0.0953
0.0006
0.5850
NP-NH2 25 ug/mL
0.2096
0.0002
0.0001
NP-NH2 50 ug/mL
0.0001
0.0002
0.0001
NP-NH2 100 ug/mL
0.0006
0.0002
0.0001
Heparin 1.56 ug/mL
0.4895
0.0801
0.3836
Heparin 6.25 ug/mL
0.5808
0.0070
0.0001
Heparin 25 ug/mL
0.6807
0.7478
0.0318
Heparin 100 ug/mL
0.4716
0.0006
0.0006
Heparin 400 ug/mL
0.1900
0.1093
0.7762
Heparin 1600
0.4760
0.0006
0.0001
ug/mL
Table 5.1 Summarization of P-values from a two-tailed TTest compared against control
group means. Cells highlighted with green show P-values less than 0.05

Figure 5.4 Comparison of MTS assay results of heparin-coated nanoparticles (left) and
Raw Heparin solutions (right) by cell type. Heparin loading of 2.956 µg heparin per µg
nanoparticle.
Live/Dead assays confirmed the cell death seen in the MTS studies for higher
concentrations of NP-NH2 particles and also showed toxic effects for NP-Hep particles as
concentrations rose. This allows comparison of MTS cell viability for proliferation versus
toxicity. These studies show a significant drop in cell viability at 10 µg/mL of heparin
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coated nanoparticles for VSMCs. Similar effects were seen for PECs and 3T3s, though in
less dramatic quantities. These results are summarized in Figure 5.5.

Figure 5.5 Live/Dead assay showing effects of nanoparticle and heparin concentrations
by cell type.
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Figure 5.6 Images of Live/Dead Assay fluorescence showing live 3T3s in green and dead
cells in red.

Figure 5.7 Images of Live/Dead Assay Fluorescence showing live VSMCs in green.6
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Figure 5.8 Combined data comparing relative cell viabilities from MTS and Live/Dead
assays for VSMCs exposed to heparin-coated nanoparticles for 48 hours. Heparin loading
of 2.956 µg heparin per µg nanoparticles.
Immunofluorescent staining was conducted on each cell type using appropriate
markers to observe correct function and phenotype changes. Special attention was given
to VSMCs, monitoring actin alignment as a phenotype marker. Though quantification of
phenotype changes of VSMCs was beyond the scope of this study, a general trend was
observed for spindle-like shaping of VSMCs exposed to higher concentrations of heparin
via nanoparticles. This helps validate findings by MTS assays, though more specific
markers may be necessary for assurance and quantification of trend. Images of the results
of this are seen below in Figure 5.9.
Endothelial cells and Fibroblasts were additionally stained for VE-Cadherin and
Collagen Type 1 markers, respectively. Imaging using the EVOS system did not allow
high detail in analysis, so results and conclusions could not be made. Confocal
microscopy may allow high magnification, though cell-seeding methods would need to
be adjusted. A selection of images can be seen below in Figure 5.10.
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a) Control

b) Control

c) 1 μg/mL NP-Hep

d) 10 μg/mL NP-Hep

e) 25 μg/mL NP-Hep

f) 1 μg/mL NP-NH2

g) 10 μg/mL NP-NH2

Figure 5.9 Immunofluorescent staining of VSMCs to observe phenotype changes.
Smooth muscle actin is seen in green. Nuclei are seen in blue.

a) 3T3 Control

b) 3T3 25 μg/mL NP-Hep

c) PEC Control

d) PEC 10 μg/mL NP-Hep

e) PEC 25 μg/mL NP-Hep

f) PEC 1 μg/mL NP-NH2

Figure 5.10 Samplings of images from immunofluorescent staining of 3T3 Fibroblasts
and PEC Endothelial Cells.
94

5.5 Discussion
Prior work within our lab to determine cell uptake of particles has suggested the
Prussian Blue Stain for iron particle presence. This stain does not work as a true stain, but
rather works as a histochemical reaction to change color.4 The working solution uses two
parts for this process. The 4% hydrochloric acid works to split off any bound proteins,
allowing the 4% potassium ferrocyanide to bind and form ferric ferrocyanide. This
produces a blue color that should be visible without microscope and is specific enough to
show even single iron particles.5 Previous results suggested the darker sections to be the
presence of the iron nanoparticles agglomerated within the cell. However, our testing
with particles does not result in the blue solution color expected with iron presence, even
with particles injected directly into the working solution. This may suggest that the
polymeric coating has hindered bonding between the iron oxide and potassium
ferrocyanide. Further testing to demonstrate the efficacy of the Prussian Blue stain will be
needed, such as by direct injection of an alternative iron source and verification of cell
uptake.
To verify the uptake that was previously suspected in cells, TEM imaging was
attempted. Success of this process would adequately show the presence of nanoparticles
within the cell. However, this process has proven to be particularly difficult for our
application. Under typical cell TEM imaging, cells may be directly plated onto a glass
slide, dried, and imaged. However, these techniques look mostly at surface structures of
cells, while proof of uptake requires looking into cell. Thus far, this process has proven to
be very tedious as cells must be fixed and cut without spilling interior contents. To
accomplish this, it has been suggested that cells be embedded in resin and then cut by
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microtome in slices between 70-90 nm thick. This process requires several steps to resin
application to insure resin infiltrates the cell membrane for removal. Literature has shown
this process, often detaching cells with Trypsin and cutting slices out of an embedded cell
pellet. However, as VSMCs are adherent cells, it is our concern that contents may be
spilled out upon detachment, invalidating any results. To accommodate this, initial
attempts tried to embed resin in cells fixed within a 96-well plate. However, the hard
plastic proved nearly impossible for clean resin removal with intact cell membranes.
Further attempts have worked on attachment of cells to glass slides and within material
resin tubes, both coated with polylysine. However, to date these attempts have been
unsuccessful.
MTS studies of each cell line were largely successful. When compared to
previous results, the newest batch of particles tested on VSMCs showed similar results at
lower concentrations than prior data. This was expected from the higher heparin loading
of the new batch. The most interesting results were found by administration of heparinloaded nanoparticles to endothelial cells. Our results found that in response to increases
in concentration of both these particles and raw heparin, the endothelial cells increased in
proliferation. This effect may be especially beneficial for application of treatment of
neointimal hyperplasia, as proliferation of endothelial cells may additionally kick-start
the healing process for the vessel wall.7 Some studies have suggested heparin inhibition
of endothelial cell proliferation, with maximum effects for heparins of 6 kDa.11 This same
study found heparin proliferation inhibition to occur down to 3 kDa, the weight of
heparin on our nanoparticles. It further suggest that inhibition requires >8 saccharide
units. Lack of proliferation inhibition may occur as a result of bound heparin reducing
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available saccharide unites. Additionally, it was also noted that amine terminated
particles gave higher MTS readings for PECs, suggesting that the nanoparticle interaction
further plays a role. Additionally, as discussed above, as endothelial cells require shear
stresses, tests in simulated environments may be required for accurate proliferation
results of endothelial cells.
Live/Dead analysis shows similar results to MTS assay, but with focus on the
percentage of living cells. As seen in the side-by-side comparisons, the key differences
between the MTS and Live/Dead assays are seen at the lowest concentration of heparincoated nanoparticles, 1 µg/mL. At this concentration, the average cell viability of MTS
assay was found to be significantly lower while the average cell viability for the
Live/Dead assay was not found to be significantly different. This has led to our belief that
the optimal dosing (for heparin loadings of between 2.8-3.0 µg heparin per µg
nanoparticles) lies somewhere between 0 -10 µg/mL nanoparticles. To further determine
this dosing, future studies will be required with delineations within this range.
To

accurately

determine

and

verify

results

seen

in

MTS

assays,

immunofluorescence staining was used to begin classification of phenotype changes.
While this staining of VSMCs allows some preliminary, qualitative analysis of
phenotypic changes, some further action is needed to begin quantitative analysis and
verification of this stain. This future testing could use one of several options, including
looking at more specific marker proteins such as smooth muscle-heavy chain myosin and
smoothelin-A/B. While our staining of alpha-smooth muscle actin is present in both
phenotypes, some of these other marker proteins are all present in contractile cells.8,9
Using a combination of these markers with the alpha smooth muscle actin would allow
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more accurate identification of contractile cells. As an alternative or for further
validation, atomic force microscopy (AFM) may be used to measure cell elastic modulus,
where contractile cells have a much higher modulus as a result of organized actin.10
Additionally, use of Polymer Chain Reactions (PCR) and/or western blotting will allow
quantification of these phenotype changes.10
VE-Cadherin staining was used for PEC immunofluorescence due to its role in
regulating cell proliferation and apoptosis.13 This molecule is an endothelial cell specific
adhesion molecule located at junctions between cells.13 By imaging this molecule, we can
compare endothelial cell interactions across experimental and control cultures. In
particular, VE-cadherin works to mediate proliferation signals, helping with explanation
of the MTS proliferation increases seen. Unfortunately, fluorescent imaging of VEcadherin showed spread out endothelial cells, lacking interaction at cellular junctions.
This may be the result of nanoparticle-VE-cadherin interactions or simply loss of cells
during fixation. Further staining will be required to determine this relationship.
Collagen Type 1 was chosen for recognition of fibroblasts, taking advantage of
fibroblast as the major producer of collagen.14 As can be seen in the images of
Fibroblasts, fluorescence of collagen in green is very apparent in both control and
experimental conditions above the effective dosing. Further studies should work to
provide quantification of collagen production.
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CHAPTER SIX
CONCLUSIONS AND RECOMMENDATIONS
6.1 Conclusions
Despite new advancements in preventive care, neointimal hyperplasia continues
to pose a significant threat following any angioplasty procedure. Drug-eluting stents
(DES) have proven to be an effective step in the right direction, reducing prevalence
significantly. For cases when these fail, nanoparticles show promise for follow-up
treatment for neointimal hyperplasia and across the field of biomedicine.
This study successfully combined previous synthesis efforts of heparin-coated
magnetic nanoparticles with our current work, demonstrating the potential to load large
amounts of drugs onto nanoparticle vessels. This loading was successful in both small
scale and bulk scale batches. We have explored the potential of magnetic nanoparticles
and heparin separately and conducted preliminary studies to characterize potential use via
in vitro studies. These synthesized particles were used to test for cellular uptake,
proliferation effects, cytotoxicity, and phenotype changes in vascular smooth muscle cells
(VSMCs), endothelial cells, and fibroblasts.
Under ideal circumstances, a drug for neointimal hyperplasia would be
biocompatible and able to be targeted directly to the site of injury, rather than by systemic
delivery. It would enter targeted cells and reduce cell number without inducing cell death,
suggesting a reduction in proliferation by inducing the contractile phenotype of VSMCs.
Finally,

this

drug

would

initiate

endothelial

cell

proliferation,

promoting

endothelialization of the damaged vessel and starting the healing process. While the
results from this study do not make these particles market-ready, they are promising for
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addressing all of these concerns in neointimal hyperplasia via heparin-coated magnetic
nanoparticles.

6.2 Recommendations
Although our initial results are promising, there are several necessary steps to
prepare for more advanced trials. Our results indicate effective nanoparticle
concentrations (at current heparin loadings) to be below 10 µg/mL. Thus, further work
will be required to exact this dosage within the range of 0-10 µg/mL. Additionally, to
insure the findings of this study to be accurate more tests may be required (and are
currently underway) to give accurate standard deviations and error for all tests. Once
heparin loading and dosing has been optimized, further work to characterize the storage
life of particles should be conducted.
To validate cell uptake, an assay other than the Prussian Blue stain is necessary.
TEM promises to be the most accurate, though some new protocols will be required.
Cryofixation of cells at another facility may be required to allow imaging inside of
attached cells. While preliminary results for phenotype changes show promise, further
testing should be conducted to validate these findings. It would be recommended to look
into other phenotype markers for VSMCs, especially those specific to contractile
phenotypes. Imaging these markers at higher resolutions using confocal microscopy,
polymer chain reaction (PCR), and/or western blot would allow verification and
quantification of phenotype changes.
Once further evaluation of cellular effects has been conducted, nanoparticles will
need to be evaluated for magnetic properties. Though assumed to exhibit
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superparamagnetic properties, tests to verify this are needed. Additionally, these
properties will need to be tested in both a simulated blood flow environment, along with
in vivo environments to insure adequate magnetic forces can be reached to pull particles
out of blood flow.
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Appendix A: Magnetic Nanoparticle Thermodecomposition
Written by: Andrew Hargett
This process follows a modified version of Sun’s method for thermodecomposition of
magnetite nanoparticles.
Materials:
• Iron (III) acetylacetonate (Fe(acac)3) from Fluka or similar
• Oleic acid from Alfa Aesar or similar
• Three-neck round bottom flask
• Overhead stir bar
• Hexanes
• Centrifuge tubes (size depends on quantity)
• Acetone
• Tetrahydrofuran (THF) from Fisher Scientific or similar
• Bio Beas S-X1 Support in 40cm long, 2.5cm diameter glass GPC tube
Methods:
1. Combine Iron (III) acetylacetonate (as the iron precursor) with oleic acid (as the
ligand) in a 1:15 molar ratio in the three-neck round bottom flask. Allow the
reaction to take place under flowing nitrogen at 0.1 L/min while stirring with an
overhead stir bar. As an example, we used 1.078g (3mmol) to 13.48 (47.6 mmol).
2. Heat the solution to 360oC for one hour.
3. Allow the solution to cool to room temperature and suspend in hexanes for
transfer to centrifuge tubes.
4. Wash with acetone three times, then re-suspend in hexanes.
5. Leave solution in drying oven for 48 hours to remove any remaining solvent.
6. Suspend dried particles in THF and purify in a THF GPC column with
pressurized 5 psi N2 gas.
Reference:
1. S. Sun and H. Zeng, “Size-Controlled Synthesis of Magnetite Nanoparticles,”
Journal of the American Chemical Society, 124:8204-5, 2002.
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Appendix B: Magnetic Nanoparticle PEGylation Ligand Exchange and Amine Terminal
Group Addition
Written by: Andrew Hargett
This process conducts a ligand exchange of oleic acid coated magnetite nanoparticle. The
terminal alcohol group is changed to an amine. See additional protocol for synthesis of
nitroDOPA polymer.
Materials:
• nitroDOPA anchors attached to 1,800 g/mol poly(acrylic acid) (Sigma-Aldrich)
with a 8,000 g/mol poly(ethylene glycol) (Sigma-Aldrich) spacer terminated in an
alcohol.
• Chloroform
• Nanoparticles suspended in THF
• Dichloromethane (DCM) from Acros Organics or similar
Methods:
1. Dissolve excess polymer in 5 mL of chloroform while back filling with nitrogen
gas. Note: We used 250 mg polymer.
2. Remove THF from particles using rotary evaporation.
3. Suspend particles in 5 mL of chloroform and add drop-wise to the polymer
solution under sonication over 15 min.
4. Agitate by shake plate or sonication for 2-7 days.
5. Purify using a THF GPC column to remove excess polymer.
6. Dry particles to a powder using rotary evaporation and suspend in deionized
water. Some particles may be kept at this step for analysis and cell testing.
7. Wash particles in a water GPC column.
8. Freeze dry particles to a powder and suspend in 10 mL of DCM.
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Appendix C: Heparin modification of amine terminated, PEGylated magnetic
nanoparticles
Written by: Andrew Hargett
This process first changes the terminal group of the attached nitroDOPA polymer from an
alcohol group of carboxylic acid to an amine group. It then attaches heparin.
Trethylamine is utilized as a scavenger for the acid.
Terminal Group Exchange
Materials:
• 3-chloropropylamine from Sigma or similar
• dichloromethane (DCM) from Acros Organics or similar
• Triethylamine from Fisher Scientific or similar
• Nanoparticles suspended in DCM
Methods:
1. Excess 3-chloropropylamine was dissolved in 5mL of DCM.
2. Suspend nanoparticles in
3. Add trimethylamine to the 3-chloropropylamine solution in a molar ratio of 1:3.
4. Add nanoparticles drop-wise and agitate by shake plate or sonication for 2 days.
5. Take 2.5 mL aliquots of nanoparticle solution and transfer to 50 mL centrifuge
tubes filled with 40 mL ether. Centrifuge for 10 min at 10,000 rpm to remove
excess chloropropylamine by precipitation.
6. Dry in a vacuum oven under vacuum and no heat.
7. Freeze dry to remove any excess DCM.
8. Suspend particles in deionized water and purify using a water column.
9. Freeze dry to a powder and suspend in deionized water.
Heparin Modification
Materials:
• Nanoparticles suspended in water
• Heparin (MW 3000 g/mol, MP Biomedicals)
• EDC from TGI or similar
• Sulfo-NHS from Thermo Scientific or similar
Methods:
1. Use the Iron Determination Assay to find iron concentration and calculate
estimated number of free ligands in solution. Note: We assumed 6 free ligands
per nm2 of nanoparticle surface area.
2. Calculate molar ratios of 1 free ligand : 3 heparin : 30 EDC : 65 sulfo-NHS
3. Dissolve heparin, EDC, and sulfo-NHS in deionized water and allow to
equilibrate for 15 min.
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4. React with nanoparticle solution for 24 hours at room temperature. Note: This
time frame was adjusted from pilot batches at 12 hours reaction.
5. Remove excess heparin by washing through a water column.
6. Freeze dry to a powder and suspend in known quantity of deionized water.
7. Characterize particles using Iron Determination Assay and DMMB Assay.
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Appendix D: Fe Determination Protocol – Up to 400ug Fe
Written By: Elliot Mappus
Updated: Andrew Hargett 3/21/16
Iron Working Solution Preparation:
1. Obtain desired iron sample for test.
2. Transfer 5-8uL for concentrated samples or 100uL for dilute samples to a
10mL volumetric flask with a calibrated 10uL pipette. Note: Use one of the
short-necked flasks to allow the pipette to reach the bottom of the flask. Place
drop in center. We found 50uL to work well.
3. Dissolve the iron in he flask with approximately 0.2mL of concentrated HCl
for 15 seconds.
4. Fill the flask with deionized water to the 10mL mark to form the iron stock
solution. Top with a ground glass stopper and mix by inverstion 3 times.
5. Transfer the solution to a disposable 15mL centrifuge tube and mix by
inversion.
Color Working Solution Preparation:
• Hydroxylamine hydrochloride solution (100 g/L) – dissolve 1 g of hydroxylamine
hydrochloride in 10 mL nanopure water.
• 1,10-phenanthroline solution (3 g/L) – dissolve 0.3 g of 1,10-phenanthroline
monohydrate in 10mL of methanol and dilute to 100 mL with nanopure water.
• Ammonium acetate-acetic acid solution – dissolve 10 g of ammonium acetate in
about 60 mL of water, add 20 mL of glacial acetic acid, and dilute to 100 mL with
nanopure water. Sodium acetate may be used in place of ammonium acetate.
Sample Preparation:
1. Using a calibrated 1mL pipette, transfer 0, 0.5, 1, 1.5, 2, and 2.5 mL of iron
working solution to several 15 mL centrifuge tubes.
2. Dilute each centrifuge to 6mL with deionized water.
3. To develop color:
a. Add 0.2 mL of hydroxylamine hydrochloride solution to each
centrifuge tube and swirl to mix.
b. Add 0.5 mL of 1,10-phenathroline solution to each centrifuge tube and
swirl to mix.
c. Add 0.75 mL of ammonium acetate-acetic acid solution to each
centrifuge tube and swirl to mix.
d. Dilute each tube to 10 mL with nanopure (DI) water using a pipette.
Mix by inversion.
4. Transfer ~3 mL from each flask to a disposable PMMA cuvette, doubling the
tube with 0 mL of working solution to use as a blank for UV/Vis calibration.
Measure Absorbance:
1. Measure all samples using a UV/Vis spectrophotometer.
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2. For each sample, record the absorbance at 511 nm (the Fe peak) and at 690
nm (the baseline).
3. Subtract the 690 nm absorbance from the 511 nm absorbance and insert value
into iron determination spreadsheet.
Cleaning Procedure Notes:
1. Glassware should be stored in the drying oven and rinsed twice with DI water
following use.
2. After stock solution is made, add 3 mL of concentrated HCl to the volumetric
flask. Swirl for 30 seconds and dispose of the acid.
3. Rinse Volumetric flask twice with water in the fume hood, then twice outside
of the fume hood.
4. Make the iron working solution immediately prior to measurements.
5. Color working solutions may be made several months in advance.
Reference: ASTM, E 394-0
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Appendix E: DMMB Standard Curves
Written by: Elliot Mappus
Comparison of heparin and chondroitin sulfate standard curves. The difference in slopes
was found to be not statistically significant (P>0.4).
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Appendix F: DMMB Assay
Written by: Alex Lindburg – MBEM Lab
Updated: Andrew Hargett 3/21/16
DMMB Working Solution:
1. Dissolve 16 mg of DMMB dye in 1 L of nanopure water.
2. Add 3.04 g 99%+ pure glycine, 2.37 g NaCl, and 95 mL of 0.1 M HCol.
3. Stir with a stir-bar to mix thoroughly.
4. Filter through Watman paper, discard if there is any precipitate.
5. This solution may be stored at room temperature and protected from light for
up to 2 months.
Standard Curve Generation:
1. Make an initial working solution of 100 µg/mL GAG by adding 2.0 mg
Chondroitin sulfate powder to 20 mL of PBS.
2. Dilute appropriately to make final GAG working solutions of 0, 12.5, 25, 50,
75, and 100 µg/mL
Working Solution (µL)
0
25
50
100
150
200

PBS (µL)
200
175
150
100
50
0

Final Concentration (µg/mL)
0
12.5
25
50
75
100

3. Add 180 µL of DMMB working solution to 18 wells of a U-bottom 96-well
plate.
4. Add 20 µL of GAG working solutions to wells in triplicates and shake for 5
seconds.
5. Read absorbance at 530 nm using a microplate reader.
Notes: The standard curve comparing chondroitin sulfate to heparin has been provided in
Appendix C. This linear correlation is limited to between 10 and 50 µg/mL or 0.2 and 1.0
µg in 20 µL of solution.
Reference:
Mort, JS and PJ Roughly. Measurement of glycosaminoglycan release from cartilage
explants. (2007) Methods in Molecular Medicine. 135, 201-209.
Heparin Loading Calculation:
1. Create working solutions of nanoparticles at 0, 10, 20, 30, 40, and 50 µg/mL
in water.
2. Mix 20 µL of each nanoparticle working solution with 180 µL DMMB
working solution in triplicates in a U-bottom 96-well plate.
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3. Read absorbance using a microplate reader at 530 nm.
4. Absorbance values must be converted to corresponding GAG concentration
using the chart in Appendix C. For heparin, divide absorbance values by
0.0276 and then average the triplicates.
5. Using Excel, plot the heparin loading as GAG concentration (y-axis) from
number 4 against concentration from number 1. Resulting slope is heparin
loading in µg heparin per µg nanoparticle.
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Appendix G: General Cell Culture
Written by: Andrew Hargett
Cell Thawing
1. Select cells previously frozen at 5 x 10^5 cells per 1 mL media for each cryovial
and 5% dimethylsulfoxide (DMSO) in liquid nitrogen.
2. Allow cells to completely thaw in room temperature.
3. Mix High Glucose Dulbecco’s Modified Eagle’s Medium (DMEM) by Gibco or
similar, 10% fetal bovine serum (FBS) by Atlanta Biologicals or similar, and 1%
penicillin/streptomycin (AA) by HyClone or similar to make complete cell
medium (CCM).
4. Pipette 10 mL of CCM into a sterile 15 mL centrifuge and warm in a water bath.
5. Transfer warmed CCM to a T-75 flask and seed cells.
6. Incubate cells at 37oC and 5% CO2 and monitor for attachment. Note: Cells
should attach within 24 hours in alive.
7. Wait 24 hours, then aspirate old media and pipette 10 mL of warm CCM into the
flask.
8. Change media every 48-72 hours, monitoring for cell confluence and CCM pH
change.
Cell Passaging
1. Once cells have reached 70-90% confluence, begin cell passaging.
2. Aspirate T-75 flask of old media and was 2x with Sterile Phosphate Buffered
Solution (PBS) for 30 sec each.
3. Transfer 5 mL of Trypsin solution, made with PBS, 0.25% trypsin, and 0.02%
ethelendiaminetetraacetic acid, into the flask and incubate for 5 min.
4. Check cells for complete detachment and aid with light percussive therapy as
required.
5. Transfer cell suspension to a 15 mL centrifuge tube at centrifuge at 1000 rpm for
5 min (vascular smooth muscle cells and fibroblasts) or 1200 rpm for 6 min
(endothelial cells).
6. Aspirate CCM and Trypsin, leaving pellet in bottom of centrifuge tube.
7. Suspend cells in 1 mL of warm CCM.
8. Remove and dilute a small portion for cell counting.
9. Seed cells as required and seed unused cells in a new T-75 flask for later
passaging.

114

Appendix H: Prussian Blue Protocol
Written by: Andrew Hargett
Sample Preparation:
1. Seed cells at 5,000 cells/well into a 96-well plate in standard media.
2. Incubate in standard media for 24 hours and check for cell attachment.
3. Aspirate media and replace with experimental solutions and control
parameters diluted in media in duplicates. Notes: Our solutions included
nanoparticle concentrations of 0, 1, 10, and 25ug/L. Experimental media was
administered with 120 µL per well.
4. Incubate for 2 hours or as desired and check for cell attachment.
5. Aspirate media and wash with PBS 3x.
6. Fix cells using 4% Paraformaldehyde (PFA) for 20-30min at room
temperature. Use same volume as experimental solutions.
Prussian Blue Staining:
1. Mix a working solution of 4% potassium ferrocyanide and 4% hydrochloric
acid in equal parts.
2. Cover cells with working solution for 10min at room temperature. Aspirate
and repeat for another 10min. We recommend using same volume working
solution as experimental solution.
3. Wash with PBS twice.
4. Counterstain with Nuclear Fast Red for 3min. We recommend using just
enough to cover cells.
5. Was with PBS twice and leave in 3rd rinse of PBS.
6. Image using an Olympus CKX41 microscope or similar.
Notes:
• Prussian Blue is not a true stain and does not fluoresce. It works by binding to
ferric ions, creating the bright blue pigment Prussian Blue, or ferric ferrocyanide.
• Solution color change to blue should be apparent without use of microscope.
• Use working solution within 60min of mix.
• Cells may be stored at 4 degrees C with stable color for up to 24 hours.
• You may wish to leave the working solution on for longer and wait for a blue
color to develop that may be seen without magnification. This indicates the
presence of iron.
Reference:
BioPAL. Prussian Blue Staining of Cells in Culture Protocol.
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Appendix I: MTS Assay Protocol
Written by: Andrew Hargett
Sample Preparation:
1. Seed cells at 2,000 cells/well into a 96-well plate in standard media.
2. Incubate in standard media for 24 hours and check for cell attachment.
3. Aspirate media and replace with experimental solutions and control
parameters diluted in media in duplicates. Notes: Our solutions included
nanoparticle concentrations of 0, 1, 10, 25, 50, and 100 µg/L as well as
heparin solutions with concentrations of 1.56, 6.25, 25, 100, 400, and 1600
µg/mL. Experimental media was administered with 120 µL per well.
4. Control conditions were created using standard media and wells without any
cells seeded.
5. Incubate for 48 hours or as desired and check for cell attachment.
6. Aspirate experimental media and wash with sterile PBS 3x.
MTS Assay:
1. Mix the working solution from a CellTiter Aqueous One Solution Cell
Proliferation Assay kit by Promega with standard media in a ratio of 1:5 by
volume.
2. Aspirate PBS from washing.
3. Add MTS solution diluted in media in same volume as experimental
conditions. Include several wells without cells (blanks) for background
calibration.
4. Protect from light and incubate from 1-4 hours. Note: Our lab has found 2
hours to give optimal measurements.
5. Measure absorbance at 490 nm using a microplate reader.
6. Average all blanks and subtract from each absorbance to factor out
background noise.
7. Average control well absorbance values for baseline.
8. Compare all experimental absorbance values as a proportion relative to the
control absorbance values.
Notes:
• This kit works as a colorimetric method to assess the number of viable cells in
proliferation, cytotoxicity, and chemosensitivity. It should be used in conjunction
with a Live/Dead assay for full picture.
• The MTS tetrazolium compound, [3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium], reacts with live,
attached cells to form a colored product, formazan.
• MTS mixture should be made immediately prior to use and protected from light.
The MTS compound can be frozen long term or kept in refrigeration for several
months. Avoid freeze-thaw cycles.
• Cells may be reused following MTS for further assays.
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Appendix J: Live/Dead Assay Protocol
Written by: Andrew Hargett
Sample Preparation:
1. Seed cells at 20,000 cells/well into a 24-well plate in standard media.
2. Incubate in standard media for 72 hours and check for cell attachment.
3. Aspirate media and replace with experimental solutions and control
parameters diluted in media in duplicates. Notes: Our solutions included
nanoparticle concentrations of 0, 1, 10, 25, 50, and 100 µg/L as well as
heparin solutions with concentrations of 1.56, 6.25, 25, 100, 400, and 1600
µg/mL. Experimental media was administered with 400 µL per well.
4. Control conditions were created using standard media and wells without any
cells seeded.
5. Incubate for 48 hours or as desired and check for cell attachment.
6. Aspirate media from 2 control wells and create a negative control by
incubating for 30min with 400 µL of 70% ethanol.
7. Aspirate experimental media and ethanol and wash with sterile PBS 3x.
Live/Dead Assay:
1. The Live/Dead Viability/Cytotoxicity kit by Life Technologies was used to
create working solutions of calcein acetoxymethyl (Calcein) and ethidium
homodimer-1 (Etd-1).
2. Working solutions were made of approximately 10mL of 2 µM ethidium
homodimer-1, 4 µM calcein AM, and a combination of each.
3. All experimental conditions receive treatment of the combination solution.
4. Positive and negative controls are made by adding solutions of ethdium
homodimer-1 and calcein AM separately to control live and control dead cells.
5. Incubate all conditions for 30 min protected from light.
6. Image using an EVOS FL Microscope under Red/Green fluorescence for
qualitative data.
7. Measure fluorescence using a microplate reader at 485nm excitation to 530nm
for live cell emission and 530nm excitation to 645nm for dead cell emission.
8. See manufacturer instruction for calculation of percentage of live and dead
cells.
Notes:
• Live cells will appear as green on imaging. Dead cells will appear as red.
• Make sure to measure fluorescence and not absorbance on the microplate reader.
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Appendix K: Immuno-fluorescent Staining Protocol
Written by: Andrew Hargett
Sample Prep:
1. Seed cells at 2,000 cells/well into a 96-well plate in standard media.
2. Incubate in standard media for 24 hours and check for cell attachment.
3. Aspirate media and replace with experimental solutions and control
parameters diluted in media in duplicates. Notes: Our solutions included
nanoparticle concentrations of 0, 1, 10, 25, and 50 µg/L. Experimental media
was administered with 120 µL per well.
4. Incubate for 48 hours or as desired and check for cell attachment.
5. Aspirate media and wash with PBS 3x.
6. Fix cells using 4% Paraformaldehyde (PFA) for 20-30min at room
temperature. Use same volume as experimental solutions. Cells may be left at
this stage in refrigeration for long term.
Staining:
1. Rinse with PBS
2. Permeabilize with 0.3% Triton-X 100 for 15 at room temperature
3. Rinse 3x with PBS for 5min each
4. Block with blocking agent containing 5% BSA and 0.05% Triton-X 100 in
PBS for 1 hour
5. Rinse 3x with PBS for 5min each
6. Rinse with 5% donkey serum/1% BSA/PBS for 30 min
7. Rinse 3x with PBS
8. Incubate with Primary Antibody diluted in PBS overnight at 4oC
9. Rinse 2x with 1% BSA/PBS
10. Rinse with 5% donkey serum/1%BSA/PBS
11. Rinse 3x with PBS for 5min each
12. Incubate with Secondary Antibody diluted in PBS for 1 hour at room
temperature protected from light.
9. Rinse 3x with PBS
10. Incubate with DAPI at 300nM diluted in PBS for 5 min at room temperature
11. Rinse 3x with PBS, leave in final change.
12. Image cells.

118

